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“True ease in writing comes from 
art, not chance, as those who move 
easiest have learned to dance” 
Alexander Pope 
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MAIN ABBREVIATIONS AND TERMS 
CD14 Cluster of differentiation 14 
CDCA Chenodeoxycholic acid 
Cr-EDTA Chromium ethylenediaminetetraacetic acid 
DCA Deoxycholic acid 
DSS Dextran sodium sulphate 
E% Per cent of total dietary energy 
FITC Fluorescein isothiocyanate 
FXR Farnesoid X receptor 
HIx Hydrophobicity index 
HF High-fat diet 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome 
JAM Junctional adhesion molecule 
LPS Lipopolysaccharide 
MLCK Myosin light chain kinase 
LBP Lipopolysaccharide binding protein 
LPS Lipopolysaccharide 
TER Transepithelial electrical resistance 
UDCA Ursodeoxycholic acid 
ZO Zonula occludens 
Endotoxin: A toxic heat-stable lipopolysaccharide substance present 
in the outer membrane of gram-negative bacteria that is released from 
the cell upon lysis
Intestinal permeability: Translocation  of  a  molecule  that  is  not  
actively absorbed through the gut epithelium, used synonymously with 
barrier function, since these two may not always be distinguished due 
to limitations in methodology 
Metabolic endotoxemia: A low-grade but significant endotoxemia 
where serum endotoxin levels are approximately 2-fold compared to a 
healthy state 
Translocation: Passage of a molecule through an epithelial layer by an 
undefined mechanism 
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ABSTRACT
Gut barrier function is impaired in several disorders such as 
inflammatory bowel diseases, diabetes and steatohepatitis. It is 
suspected that this is related to increased permeability to bacterial 
endotoxins from the lumen through the gut epithelium. Recent studies 
have shown a link between high-fat diet and endotoxemia, but the 
underlying mechanisms are unknown. One possible explanation is the 
contribution of other luminal substances, such as bile acids. Fat 
ingestion induces bile flow to the duodenum to facilitate the absorption 
of fat. At high concentrations, bile acids – especially very hydrophobic 
bile  acids  –  are  cytotoxic.  The  aim  of  this  study  was  to  investigate  
whether dietary fat or obesity causes barrier dysfunction, and whether 
bile  acids  play  a  role  in  its  pathogenesis.  The  role  of  bile  acid  
hydrophobicity in their capability of inducing barrier dysfunction was 
given special attention. 
The effects of dietary fat and obesity on gut barrier function were 
investigated in the diet induced obesity and ob/ob -mouse models. 
Fecal bile acids were quantified and profiles calculated from these 
mice. The effects of bile acids on intestinal permeability were studied in 
an in vivo feeding trial with deoxycholic acid and in vitro in an Ussing 
chamber. In vitro, tissue preparations were incubated with deoxycholic 
acid and/or ursodeoxycholic acid - two bile acids greatly different in 
their hydrophobicity. 
ABSTRACT 
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Gut barrier function was impaired by a high-saturated fat diet in mice, 
but not in genetically obese mice that were fed normal low-fat chow. 
Barrier dysfunction by dietary fat was especially prominent in jejunum 
and colon - no significant difference was seen in the permeability of 
duodenum or ileum. Fecal bile acid hydrophobicity was increased only 
by dietary fat, not by genetic obesity, and was positively correlated with 
intestinal permeability. 
Deoxycholic acid alone increased gut permeability both in vivo and in
vitro. The effect was more evident in colonic than jejunal tissue 
preparations, and the mechanism seemed not to be inflammation-
dependent. Barrier impairment was reduced by the hydrophilic 
ursodeoxycholic acid, which was also reflected as improved tissue 
morphology. Deoxycholic acid -induced barrier dysfunction seemed to 
be aggravated by translocated lipopolysaccharides. 
The present results suggest that dietary fat, but not obesity itself, 
impairs gut barrier function. The data imply that luminal bile acids are 
one mechanism for barrier impairment, with hydrophobic bile acids 
initiating tissue disruption and lipopolysaccharides likely playing the 
role of a second hit. 
INTRODUCTION 
- 10 - 
1 INTRODUCTION 
The intestine has an essential function as a barrier between intestinal 
contents – the “outside world” – and the body (for review, see Arrieta et
al.,  2006).  The gut barrier is  impaired in several  pathologies,  some of  
them severely affecting the quality of life: inflammatory bowel diseases 
(IBD) (for review, see Goyette et al., 2007), irritable bowel syndrome 
(IBS) (for review, see Camilleri et al., 2012), type 1 diabetes (for review, 
see Vaarala, 2008), non-alcoholic fatty liver disease (for review, see 
Valenti et al., 2009) and allergy (for review, see Perrier and Corthésy, 
2011). 
Recently, impairment of gut barrier function has been linked to obesity 
and a diet high in fat (for review, see Teixeira et al., 2012a), which are 
part of the Western lifestyle.  In humans, a Western diet is suggested to 
lead to endotoxemia – an elevated level of bacterial surface molecules 
in the circulation (Pendyala et al., 2012). These pathogenic compounds 
are  expected  to  originate  from  the  gut  lumen  and  to  reflect  an  
impairment of  gut barrier function.  In the circulation,  they are highly 
inflammatory  and  may  in  part  promote  the  pathogenesis  of  type  2  
diabetes and non-alcoholic fatty liver disease (for reviews, see Cani and 
Delzenne, 2009; Valenti et al., 2009). Reducing the intestinal 
translocation of endotoxins may help prevent the metabolic disease 
burden associated with obesity. Therefore, understanding the 
INTRODUCTION 
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mechanisms underlying gut barrier dysfunction may help identify 
targets for future disease prevention and treatment. 
It  is  yet  unkown,  whether  it  is  the  dietary  fat  or  obesity  that  causes  
barrier dysfunction, and there are only suggestions upon possible 
mechanisms. Many research groups have addressed this field and 
proposed that alterations in the gut microbiome affect intestinal barrier 
function (Cani et al., 2007a, 2008, 2009; Carvalho et al., 2012; de La 
Serre et al., 2010; Serino et al., 2012). However, the gut holds a 
substantial number of other substances which may affect barrier 
function; for example bile acids. The excretion of bile acids is induced 
by ingestion of fat, as their main purpose is to solubilize dietary fat into 
a more readily absorbed form. Indeed, a high-fat diet increases their 
serum and fecal concentrations (Reddy, 1981; Suzuki and Hara, 2010). 
The fact that high levels of certain bile acids are cytotoxic to gut 
epithelium (for review, see Barrasa et al., 2013) gave rise to the 
hypothesis that alterations in bile acid composition may affect gut 
barrier function in mice on a high-fat diet. 
The purpose of this thesis was to investigate the role of dietary fat and 
bile acids in gut barrier dysfunction in mice. A specific focus was set 
on two bile acids, deoxycholic acid and ursodeoxycholic acid, which 
differ in hydrophobicity, a measure related to bile acid cytotoxicity. 
REVIEW OF THE LITERATURE 
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2 REVIEW OF THE LITERATURE 
2.1 What is intestinal permeability? 
2.1.1 Components of the intestinal barrier 
The intestinal barrier consists of several non-immunological defense 
mechanisms that together prevent luminal substances, such as 
microbes, viruses, antigens and toxins, from entering the body (for 
review, see DeMeo et al., 2002). Together with the gut immune system 
they form the so-called intestinal barrier. These mechanisms are 
summarized in Figure 1. 
In the small intestine, the gut epithelial lining sheds cells (1, Figure 1) 
and excretes fluid into the lumen (2) which dilute the intestinal 
contents and, assisted by motility, wash away potential toxins (for 
review, see Sarker and Gyr, 1992). Among luminal contents, pancreatic 
enzymes and bile have anti-bacterial effects (3) (Sarker and Gyr, 1992), 
and commensal microbes inhibit colonization of pathogens by 
competing for nutrients and secreting anti-microbials (for review, see 
Yu et al., 2012). In addition, epithelial cells secrete vast amounts of 
mucus, that inhibits adherence of luminal bacteria onto the epithelium 
(4) (DeMeo et al., 2002), and an array of antimicrobial peptides known 
as defensins secreted by epithelial Paneth cells (5) (for review, see 
Bevins et al.,  1999).  The  gut  also  secretes  immunoglobulin  A  to  bind  
REVIEW OF THE LITERATURE 
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bacterial antigens into a complex that is excreted in feces (6) (DeMeo et 
al., 2002). Together these mechanisms are called the first line of 
defense. 
The second line of defense in gut barrier function consists of the 
epithelial cells and their junctional complexes, providing a physical 
barrier between the host and lumen (7) (DeMeo et al., 2002). This is the 
most important protective component of the gut barrier. The epithelial 
barrier may be disrupted by either direct cell damage or through 
intracellular signaling mechanisms affecting cell-to-cell junctions 
(DeMeo et al., 2002). The paracellular barrier consists of four protein 
junctions: desmosomes, gap junctions, adherens junctions and tight-
junctions, of which desmosomes and adherens junctions have an 
important role in the mechanical linkage of cells (Anand et al., 2008; 
for review, see Groschwitz and Hogan, 2009). The tight junction system 
controls the paracellular flux and prevents unwanted translocation of 
harmful substances, while it allows antigen-sampling by submucosal 
immune cells (DeMeo et al., 2002). This mucosal immune system (8) 
forms the final line of defense in the gut barrier. 
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2.1.2 Pathways of endotoxin translocation 
Intestinal permeability is described as the leakage of large molecules, 
such as endotoxins (i.e. lipopolysaccharide, LPS), through the gut 
epithelium, and should be distinguished from the carrier-mediated 
absorption of dietary ingredients. However, the concept of intestinal 
permeability is not very well defined, since the probes used in the 
assessment of intestinal permeability may translocate through different 
pathways. This translocation through gut epithelium may be divided 
into two possible pathways: the paracellular pathway and the 
transcellular pathway, which may be further divided into the aqueous 
and lipid transport routes (for review, see DeMeo et al., 2002; Caesar et 
al., 2010). It is generally assumed that small molecules translocate 
through the paracellular pathway, whereas large molecules require 
transcellular transport. The following evidence suggests that this is not 
always the case. 
The paracellular pathway is guarded by tight-junctions (see 2.1.3), 
which do not normally allow passage of large molecules through the 
epithelium. However, there is some evidence indicating that even large 
molecules may translocate through the paracellular pathway, when 
induced by carbachol (Bijlsma et al., 1996) or intestinal sensitization 
(Berin et al., 1997, 1998) in the rat. Furthermore, interleukin-4 
induces the translocation of large molecules up to 150 kDa through an 
epithelial cell layer, but is not reversed by an inhibitor of energy-
dependent transport, which suggests an activation of the paracellular 
pathway (Mochizuki et al., 2009). Evidence in human ileum shows that 
in healthy conditions, LPS translocation occurs only transcellularly 
whereas in tissue specimens of patients with Crohn’s disease, LPS is 
also detected paracellularly (Keita et al., 2008). These data demonstrate 
that a paracellular pathway for LPS translocation could be induced by 
pathological conditions. 
Translocation of endotoxins is also suggested to be chylomicron-
facilitated. This was shown as an increased translocation of 
REVIEW OF THE LITERATURE 
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endotoxins, when Caco-2 cells were stimulated by fatty acids, which 
promote chylomicron formation (Ghoshal et al., 2009). Endotoxin 
translocation was blocked by an inhibitor of chylomicron formation in
vivo. In rat jejunum, fluorescence-labeled endotoxin has indeed been 
shown to be absorbed into brush-border membrane vesicles (Drewe et 
al., 2001). In humans, this hypothesis is supported by findings that a 
fat-containing meal increases postprandial plasma endotoxin levels 
(Erridge et al., 2007; Ghanim et al., 2009; Laugerette et al., 2011), 
which suggests a linkage to lipid absorption. However, these studies do 
not permit us to draw conclusions on whether the effect is specific to 
dietary fat, since results were not compared to a low-fat control meal. 
Only one study comparing cream, orange juice, glucose and water has 
demonstrated plasma endotoxemia only after fat, not carbohydrate 
ingestion (Deopurkar et al., 2010). 
In short, this evidence suggests that both pathways – 
paracellular and transcellular – are involved in 
endotoxin translocation. The paracellular pathway 
appears to be of particular importance in chronic 
disease, whereas the transcellular pathway likely 
contributes to postprandial endotoxemia. 
2.1.3 Tight-junction proteins as gate-keepers 
The tight-junction is the most apical protein complex linking epithelial 
cells together. It is a structure comprising over 50 proteins, with 
transmembrane proteins interacting with the cytoskeleton through 
plaque proteins (for review, see Ulluwishewa et al., 2011) (Figure 2). 
Tight-junction proteins include five families of transmembrane 
proteins, occludins, claudins junctional adhesion molecules (JAMs), 
the coxsackie virus and adenovirus receptor (CAR) and tricellulin, 
which is a tight-junction protein forming a linkage between three 
adjacent cells (for review, see Groschwitz and Hogan, 2009; Hossain 
and Hirata, 2008). Occludin, tricellulin and claudin are tetra-span 
proteins with four transmembrane domains and two extracellular 
REVIEW OF THE LITERATURE 
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loops, whereas JAM and CAR are single-span proteins (Hossain and 
Hirata, 2008; Ulluwishewa et al., 2011). The transmembrane proteins 
are connected to the cell cytoskeleton by intracellular proteins such as 
zonula occludens 1-3 (Ulluwishewa et al., 2011). The roles of the most 
important tight-junctions are very briefly introduced below.
Figure 2. Pathways of translocation through the epithelium with tight-
junction proteins guarding traffic through the paracellular pathway. The 
size of the enterocytes is not scaled to the size of the tight-junction 
complex. JAM = Junctional adhesion molecule, CAR = Coxsackie virus 
and adenovirus receptor, ZO = Zonula occludens. (adapted from 
Ulluwishewa et al. 2011) 
Claudins  are  vital  to  the  survival  of  an  individual  (for  review,  see  
Groschwitz and Hogan, 2009): claudin 1-/- mice die within one day of  
birth due to the lack of a proper gut barrier. Humans bear 24 genes for 
different claudins, and the responses of those proteins to defects in 
barrier function are known to differ. For example in barrier dysfunction 
in Crohn’s disease, expression of claudins-1 and -4 are unchanged, 
while claudin-5 and -8 are downregulated and claudin-2 even 
upregulated (for review, see Schulzke et al., 2009). Claudins 
demostrate size- and charge specificity which enable strict control over 
REVIEW OF THE LITERATURE 
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the paracellular flux of kations and anions (Groschwitz and Hogan, 
2009). 
Transgenic occludin-/- mice, in contrast, have normal barrier function 
despite the total lack of occludin (Groschwitz and Hogan, 2009). 
Occludin indeed seems to be more important in maintaining barrier 
function than in its formation, since occludin expression is inversely 
correlated with the translocation of FITC dextran from the 
gastrointestinal tract to serum (Cani et al., 2008, 2009). 
JAM-/- mice display compromised barrier function (Groschwitz and 
Hogan, 2009). JAMs seem to play a role especially in tight-junction 
formation, but not in barrier maintenance, because antibodies against 
JAM do not disrupt already formed tight-junctions (for review, see 
Assimakopoulos et al., 2011). 
Zonula occludens (ZO) proteins are cytosolic adaptor proteins linking 
together the cell skeleton and the transmembrane tight-junction 
proteins. There are three ZO types: ZO-1, ZO-2 and ZO-3. Of these, 
ZO-1  and  -2  are  critical  in  the  formation  of  tight-junctions  by  
recruiting claudins to the tight-junction complex (for review, see 
Marchiando et al., 2010a).
Tight-junctions are regulated by several intracellular pathways 
including myosin light chain kinase (MLCK), mitogen-activated protein 
kinases (MAPK), protein kinase C (PKC) and the Rho family of small 
GTPases (Ulluwishewa et al., 2011). Of these, the MLCK pathway is one 
of the most abundant in the gut, and is a crucial step in the regulation 
of tight-junctional permeability by several external stimuli, such as 
cytokines and pathogens (Scott et al.,  2002)  -  inhibition  of  MLCK  
prevented the deterioration of barrier function. It is well established 
that MLCK phosphorylates myosin light chain (MLC) leading to the 
reorganization of the actin cytoskeleton (for review, see Shen, 2012). 
Downstream events in tight-junction regulation are less well 
understood. It seems that MLCK induces the endocytosis of occludin 
from the tight-junction complex to intracellular vesicles, which is 
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triggered by cytokines or T-cell activation (Clayburgh et al., 2005; 
Marchiando et al., 2010b). MLCK may also affect permeability via ZO-1 
mobility from the tight-junction to the cytoskeleton (Yu et al., 2010). By 
these mechanisms, MLCK activation increases intestinal permeability. 
Another  pathway  for  tight-junction  regulation  is  the  protein  kinase  C  
pathway, which is activated by zonulin, an epithelium-derived protein 
analogical to zonula occludens toxin (for review, see Fasano, 2000). 
Zonulin-induced protein kinase C alpha activation leads to actin 
polymerization and rapid opening of the tight-junctions, and is 
suggested to have a causal role in celiac disease (Fasano et al., 2000).  
To summarize, tight-junction proteins are undoubtedly 
crucial in maintaining the gut barrier. There are 
numerous different proteins that differently regulate 
intestinal permeability. To understand how tight-
junction proteins are changed in barrier dysfunction, it 
is inadequate to analyze a single protein, since it is 
important to understand their interactions. Measuring 
the activation of regulatory pathways could also prove 
useful.  
2.1.4 Interplay of inflammation and barrier function 
Intestinal inflammation is associated with impaired barrier function, 
but  it  is  not  always  clear,  which  is  the  cause  and  which  is  the  
consequence. The intestinal barrier controls the passage of 
inflammatory substances to the submucosa, where they react with 
immune cells and cause damage via inflammation. For example in two 
mouse models of colitis, the IL-10 knock-out mouse and the dextran 
sodium sulphate (DSS) model, histological damage is associated with 
increased gut permeability (Kennedy et al., 2000; for review, see Perše 
and Cerar, 2012). The association is likely caused by the increased 
leakage of inflammatory antigens (Perše and Cerar, 2012). Moreover, 
JAM-/--mice show increased susceptibility to DSS-induced colitis 
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(Groschwitz  and  Hogan,  2009),  which  implies  that  impairment  of  the  
epithelial barrier predisposes the epithelium to inflammation. 
Inflammatory pathways also interfere with systems preserving the gut 
barrier, most notably tight-junctions (for review, see John et al., 2011). 
During an inflammatory response, the epithelium releases reactive 
oxygen  species,  nitric  oxide  and  a  broad  spectrum  of  inflammatory  
cytokines, which all contribute to barrier dysfunction. Reactive oxygen 
species are produced in the host response to intestinal bacteria, but an 
excess may lead to barrier leakage. For example, hydrogen peroxide 
can directly affect tight-junction distribution (Katsube et al., 2007) or, 
together with nitric oxide, oxidate and nitrate the actin cytoskeleton, 
which further disrupts the intestinal barrier (Banan et al., 2001). 
Hydrogen peroxide also activates nuclear factor kappa B, which leads 
to cytokine production (Schreck et al., 1991). Moreover, cytokines 
induce the production of reactive oxygen species, leading to a vicious 
cycle.
Inflammatory cytokines are normally produced by submucosal immune 
cells in response to a luminally derived trigger. Modulation of barrier 
function by inflammatory cytokines is common to several inflammatory 
gastrointestinal diseases, although the specific cytokine profile varies 
(John et al., 2011). Among the most important regulators are tumor 
necrosis factor (TNF)- and interferon (IFN)-. They increase intestinal 
permeability and lead to a redistribution of tight-junction proteins, 
which seems to depend on endocytosis of these proteins. These 
cytokines  are  proposed  to  act  through  a  pathway  involving  MLCK,  
which fosforylates MLC and leads to tight-junction disruption 
(Zolotarevsky et al., 2002). Other proinflammatory cytokines include for 
example the interleukins (especially IL-13 and IL-8), whereas 
transforming growth factor (TGF)- is immunosuppressive and has 
barrier-enhancing properties (John et al., 2011). 
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2.1.5 How is intestinal permeability measured? 
Different methods for the measurement of intestinal permeability may 
represent slightly different pathways of translocation. For direct 
measurement of barrier function, a molecular probe is introduced into 
the intestine and detected from either circulation or urine (for review, 
see Bjarnason et al., 1995). Barrier function may also be indirectly 
assessed by the analysis of tight-junction proteins or the serological 
detection of substances that are assumingly gut-derived, such as 
bacterial lipopolysaccharides. The methods for assessment of intestinal 
permeability are summarized in Table 1. 
Table 1. Methods of measuring intestinal permeability, with molecular 
probes and their sizes  
Direct measurement Indirect measurement 
In vivo 
Sugar probes (0.16-0.34 kDa) Tight-junction proteins 
Cr51-EDTA (0.34 kDa) (Portal) LPS 
FITC dextran (4 kDa) LPS binding protein
In vitro 
FITC dextrans (4-2000 kDa) 
Fluorescein (0.38 kDa) 
Horseraddish peroxidase (44 kDa) 
Mannitol (0.18 kDa) 
Trans-epithelial resistance 
Direct measurement of permeability in vivo 
Intestinal permeability may be directly defined by the permeation of a 
probe molecule.  A suitable permeability probe is water-soluble, non-
toxic, is not actively absorbed from the intestine, and not metabolized 
before, during or after translocation through the epithelium (for review, 
see Bjarnason et al., 1995; DeMeo et al., 2002). Originally, permeability 
was tested with single molecule probes (lactulose, polyethylene glycol 
[PEG], 51Cr-labeled ethylenediaminetetraacetic acid [51Cr-EDTA], 99mTc-
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diethylenetriaminopentaacetare [99mTc-DTPA]). Single-probe tests, 
however, are influenced by factors unrelated to intestinal permeability, 
such as gastrointestinal motility and renal clearance (Bjarnason et al., 
1995).  This  led  to  the  principal  of  dual  probe  tests,  in  which  the  
urinary excretion of two sugar probes, lactulose and mannitol, forms 
an index that reflects mucosal permeability. Lactulose is a larger probe 
that only translocates through the paracellular pathway when mucosal 
barrier function is impaired. Mannitol is used as an internal control, 
since it readily translocates through both paracellular and 
transcellular pathways. Comparing the urinary concentrations of these 
two probes eliminates bias caused differences in gastric emptying and 
fluid ingestion. Despite being considered the gold standard for 
permeability testing in humans, the lactulose-mannitol test has its 
pitfall for use in diabetic subjects – chronic hyperglycemia is associated 
with increased enterocyte mass (Verdam et al., 2011), which may lead 
to an increased transloaction of mannitol and false low values for 
intestinal permeability. 
Probe size determines the location of translocation, since villus tips 
contain numerous small, aqueous channels in the tight-junction 
complexes, while crypts contain fewer but larger channels (for review, 
see Arrieta et al., 2006). Thus larger probes such as lactulose, inulin 
and 51Cr-EDTA would translocate the epithelium at the base of villi 
while small probes (i.e. mannitol) may permeate tips of villi. Very large 
probes like inulin and the smallest fluorescein isothiocyanate (FITC)-
dextrans would only translocate from the crypts. 
The metabolite-properties of a sugar probe determines the site of 
intestine that its permeation reflects (Arrieta et al.,  2006).  Sucrose  is  
rapidly hydrolyzed in the small intestine, which makes it a useful 
probe for studying gastric permeability. The small intestine probes 
lactulose, mannitol, rhamnose and cellobiose, on the other hand, are 
metabolized by gut microbiota. In conditions of small intestinal 
bacterial overgrowth, the evaluation of mannitol or lactulose loss is 
impossible, and introduces a large confounding factor into the method. 
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Only probes that are stable throughout the gastrointestinal tract, such 
as sucralose and 51Cr-EDTA, are markers of colonic or whole intestinal 
permeability. Colonic permeability may be calculated by reducing small 
intestinal permeability from whole intestinal permeability. 
In animal studies, the above-mentioned in vivo methods are entirely 
applicable, although sugar probes are more rarely used. In contrast, 
the most common probes used are the radiolabeled 51Cr-EDTA and the 
fluorescence-labeled FITC-dextran, perhaps for their simple means of 
detection.  FITC-dextran is gavaged into the animal and detected from 
plasma or serum after a certain time period, most often four hours. The 
dextrans  are  commercially  available  in  sizes  ranging  from  4  kDa  to  
2000 kDa, but in vivo experiments have mainly utilized the 4 kDa 
dextran size.
Direct measurement of permeability in vitro 
Intestinal permeability is also measured in vitro from tissue samples or 
cell inserts. These studies may be conducted in an Ussing chamber 
system (for review, see Clarke, 2009), which holds the sample in 
conditions mimicking those of the intact organism: water-jacketed for 
correct temperature in physiological buffer, which is gassed to a pH of 
7.4 using a carbogen gas flow. Intestinal permeability may then be 
measured with molecular probes of various molecular weights (such as 
FITC dextran, horseraddish peroxidase, mannitol, fluorescein, cascade 
blue or lucifer yellow) or as transepithelial electrical resistance (TER), 
which can be used as a measure of the integrity of the paracellular 
pathway. In the Ussing chamber, TER is calculated from the Ohm’s law 
(U=R*I) using tissue potential difference (U) and short-circuit current 
(I). Resistance (R) is then directly influenced by short-circuit current, 
which reflects the secretion of electrolytes from the tissue, and may 
increase deviation in TER between tissue preparations. Interestingly, 
cell cultures with truncated occludin mutants (Balda et al.,  1996)  or  
occludin-targeted siRNA (Al-Sadi et al., 2011), have an increased flux of 
various kinds of small probes, but show no difference in TER. These 
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studies suggest that the flux of molecular markers and TER are in 
some situations dissociated and may reflect different translocation 
pathways. 
Indirect measurement of permeability 
Intestinal tight-junction proteins or circulatory LPS are often measured 
to indirectly describe barrier function. Naturally, tight-junction 
proteins only reflect the integrity of the paracellular pathway. 
Nevertheless, decreased expression of occludin and ZO-1 are 
associated with increased permeability to FITC-dextran (Cani et al., 
2008, 2009), which supports their importance in regulating barrier 
function. The assessment of tight-junction integrity may be complex, 
since the proper function of tight-junctions is not only determined by 
protein or mRNA level, but also by tight-junction phosphorylation, 
structure and localization (for review, see Shen, 2012). A challenge for 
the future will be to address these issues with modern high-resolution 
histological techniques. 
Impaired barrier function is often mistakenly perceived as a synonym 
to endotoxemia, because the gut is an important source of plasma 
endotoxins. Endotoxins from portal or peripheral serum/plasma are 
thus used as an indirect measure of permeability. However, the 
following concerns are related to circulating endotoxins as markers of  
barrier function (Teixeira et al., 2012a): 1) Modifications in gut 
microbiota may change the luminal  LPS concentration and lead to an 
increase in absolute translocation of LPS without a difference in 
epithelial permeability per se. 2) Altered liver clearance of LPS, for 
example due to advanced liver disease and defective Kupffer cell 
function, may affect circulatory levels and lead to false conclusions on 
the association of a disease with impaired barrier function. Because of 
these two confounding factors, circulating endotoxins do not 
necessarily describe gut permeability. 
To summarize, intestinal permeability measurements 
would ideally be performed with two different methods. 
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Endotoxins or single tight-junctions may not reflect 
changes in gut permeability, and varying translocation 
pathways complicates data comparison. Nevertheless, 
in clinical studies, dual sugar probes, in particular the 
lactulose:mannitol test, are most often used for 
permeability measurements, whereas in vivo animal 
studies rely on FITC-dextran and 51Cr-EDTA. In vitro, 
both probes and TER may be used quite reliably. 
2.1.6 Impaired gut barrier function in disease 
Impaired gut barrier function is a common characteristic of many 
diseases of systemic and local inflammation. This is because the 
intestinal barrier is a gate-keeper for the inflammatory luminal 
contents: bacteria and endotoxins. The mechanisms for impaired 
barrier function, however, have remained unknown. 
Inflammatory response by endotoxins
The participation of bacteria-derived endotoxins in sepsis was well 
known back in the 60’s (for review, see Lansing, 1963), but direct 
human evidence of an inflammatory response following endotoxin 
injection was not obtained until later (Fong et al.,  1989).  It  is  now  
known that the activation of an endotoxin-induced inflammatory 
response requires the interaction of four proteins (for review, see 
Kitchens  and Thompson,  2005):  LPS binding  protein  (LBP),  cluster  of  
differentiation 14 (CD14), the lymphocyte antigen MD-2 and the 
endotoxin receptor toll-like receptor 4 (TLR-4). On the cell-surface, 
membrane-bound CD14 (mCD14) presents LPS to a complex of  MD-2 
and TLR-4, which together activate the signaling cascade. Soluble 
CD14 (sCD14) and LBP are serum proteins that influence the potency 
of LPS to activate TLR-4 (Kitchens and Thompson, 2005). LBP binds to 
LPS and may cleave it  from bacteria to be presented to CD14. At low 
concentrations LBP promotes the transfer or LPS to the receptor 
complex and the induction of an inflammatory response. At high 
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concentrations, however, LBP is anti-inflammatory. Similarly, sCD14 
participates in the inflammatory reaction by transfering LPS to mCD14 
or the receptor complex. At high concentrations, however, sCD14 
attenuates the ability of LPS to activate the receptor complex by 
transfering LPS into lipoporteins for clearance. LBP and sCD14 seem to 
be physiological control mechanisms that prevent harmful overreaction 
to LPS. 
Endotoxin-associated gastrointestinal disease 
In inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, 
systemic endotoxaemia is correlated with disease severity (Gardiner et 
al., 1995; Pastor Rojo et al., 2007). Endotoxaemia in these diseases is 
likely caused by increased intestinal permeability and inflammation of 
the gut wall (for review, see Arrieta et al., 2006). Barrier dysfunction 
can also be observed in high-risk populations for Crohn’s disease 
without any disease symptoms (Hollander et al., 1986; Teahon et al.,
1992; May et al., 1993; Munkholm et al., 1994), indicating that 
impaired barrier function precedes disease onset. As one of the most 
used models of colitis, the interleukin-10 knock-out, does not develop 
colitis under germ-free conditions (Sellon et al., 1998), inflammation 
could be suspected to be triggered by bacterial components. 
Irritable bowel syndrome (IBS) is a functional gut disorder including 
diarrhea, constipation or both. It is usually diagnosed with a specific 
set of criteria called the Rome criteria (Engsbro et al., 2013). There is 
consistent evidence indicating that intestinal permeability is increased 
especially in patients suffering the diarrhea-predominant form of IBS, 
facilitating mucosal inflammation (for review, see Camilleri et al., 
2012). Leaking of the gut is thought to contribute to symptom severity: 
Patients with increased intestinal permeability have both visceral and 
thermal hypersensitivity and they have a higher index of disorder 
severity (Zhou et al.,  2009a).  It  is  unknown,  however,  whether  gut  
endotoxins translocate into the circulation in these patients, or if 
inflammation is only local in the gut epithelium.
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Gut-derived liver disease
One of the most investigated set of disorders related to gut barrier 
dysfunction are liver diseases, due to their direct relationship with the 
gut - the liver is the first organ to be hit by portal blood endotoxins. As 
reviewed by others in detail (Valenti et al., 2009; Seki and Schnabl, 
2012), increased intestinal permeability is hypothesized to be a key 
trigger to the onset of alcoholic liver disease and non-alcoholic 
steatohepatitis. As intestinal permeability is increased, translocated 
LPS bind to TLR-4 on the surface of Kupffer cells, hepatic 
macrophages, and induce the release of an array of cytokines causing 
liver damage. These preclinical observations are supported by data in 
humans. Patients with non-alcoholic fatty liver disease have elevated 
serum endotoxin levels (Harte et al., 2010; Volynets et al., 2012), and 
the degree of liver fat content is positively correlated with intestinal 
permeability (Miele et al., 2009). However, increased intestinal 
permeability does not correlate with the presence of steatohepatitis 
(Miele et al. 2009). This suggests that there are further triggers 
determining the pathological change from steatosis to hepatitis.
Other diseases of low-grade inflammation 
Circulatory endotoxins that have leaked from the gut are associated 
with severe inflammation in human sepsis (for review, see Vollmar and 
Menger, 2011). Unlike sepsis, low-grade inflammation involves a small 
but significant systemic inflammatory response. It is now increasingly 
evident that endotoxins, presumably gut-derived, are involved in the 
pathogenesis of several diseases. These include not only the 
inflammatory diseases exclusive to the gut and liver, but also diseases 
characterized by inflammation in other organs –  the pancreas in type 1 
diabetes (for review, see Vaarala, 2008) and joints in rheumatological 
diseases (Vaile et al., 1999; Picco et al., 2000), as shown in human 
studies. Although the role of gut barrier function in other diseases 
characterized by low-grade inflammation has not yet been thoroughly 
investigated, there is a possibility that intestinal permeability plays a 
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role in the pathogenesis of type 2 diabetes. The association of barrier 
dysfunction and endotoxemia with type 2 diabetes and obesity has 
been described in animal models (Cani et al., 2007a, 2007b, 2008), and 
evidence in obese pregnant women points to an association between 
elevated serum endotoxins and serum inflammatory markers, as well 
as macrophage infiltration in adipose tissue (Basu et al., 2011). As 
shown in large human cohort studies, low-grade inflammation is an 
independent risk factor for type 2 diabetes (Dehghan et al., 2007; Liu et 
al., 2007; Wang and Hoy, 2007). Endotoxins are assumed to derive 
from  the  gut,  and  circulating  endotoxins  are  linked  to  low-grade  
inflammation. It is then hypothesized that increased gut permeability is 
related to low-grade inflammation in humans. 
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2.2 Factors that affect intestinal permeability 
2.2.1 Fiber and other microbiome-modulating agents 
Dietary fiber exerts beneficial effects in the colon through its bacterial 
metabolite, the short-chain fatty acid butyrate (for review, see Hamer et 
al., 2008). Insoluble fibers such as cellulose and lignin are not very 
well fermented by the microbiota, whereas soluble fibers (e.g. 
oligofructose, inulin, oat bran) are more readily fermented and produce 
greater amounts of butyrate in the colonic lumen. Orally administered 
butyrate decreases intestinal permeability to 99mTc-DTPA in mouse 
mucositis (Ferreira et al., 2012) and reduces permeability of a Caco-2 
cell culture by facilitating tight-junction assembly (Peng et al., 2007, 
2009). 
Modulation of the gut microbiota, either by prebiotic carbohydrates or 
using  probiotic  bacteria  or  antibiotics,  has  an  impact  on  barrier  
function. Oligofructose and gluco-oligosaccharde, two prebiotic fibers, 
increase luminal bifidobacteria and decrease endotoxemia in both 
genetically obese and high-fat-fed mice (Cani et al., 2007a, 2009; 
Serino et al.,  2012)  -  an  effect  that  seems  to  be  mediated  through  
glucagon-like peptide 2 (GLP-2) (Cani et al., 2009). Furthermore, 
oligofructose decreases permeability of the direct marker FITC dextran 
in genetically obese mice (Cani et al., 2009). Although gut 
bifidobacteria are inversely correlated with endotoxemia (Cani et al., 
2007a,  2009),  bifidobacteria  have  not  been  proven  to  improve  gut  
barrier function. Thus it is unclear whether the prebiotic-induced 
improvement in barrier function is affected by increased bifidobacteria 
or some metabolite such as butyrate.
The  gut  microbiota  itself  is  known  to  modulate  barrier  function.  
Antibiotic treatment blunts the detrimental effects of a high-fat diet on 
barrier dysfunction, endotoxemia and inflammation, as well as 
endotoxemia induced by genetic obesity (Cani et al., 2008). The gut 
barrier may also be modulated by probiotics. Probiotics are viable, non-
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pathogenic organisms that are able to reach the intestines in sufficient 
numbers to confer benefit to the host. They affect epithelial barrier 
function by various mechanisms (for review, see Ohland and 
MacNaughton, 2010): by induction of mucus secretion, promoting host 
defensin and secretory immunoglobulin excretion, production of 
antimicrobial factors against pathogens, competing with pathogens for 
binding sites on the epithelium, and, finally, directly influencing tight-
junction structures. One of the most studied probiotics, Lactobacillus 
rhamnosus GG  (LGG),  was  reported  to  improve  barrier  function  as  
measured by the lactulose/mannitol test in children with abdominal 
pain (Francavilla et al., 2010). LGG can also prevent cow milk -induced 
barrier dysfunction in suckling rats (Isolauri et al., 1993).
2.2.2 Dietary fat and obesity 
The emerging concept 
The link between obesity, gut barrier dysfunction and endotoxemia was 
recently suggested in genetically obese mice (Brun et al., 2007). The 
authors reported decreased TER and increased HRP flux in the small 
intestine of ob/ob mice, as well as an elevated level of portal 
endotoxins.  During  the  same  year,  a  pioneering  group  from  Belgium  
reported metabolic endotoxemia in mice fed a high-fat, carbohydrate-
free diet (Cani et al., 2007a, 2007b). These reports established the 
concept of barrier dysfunction in obesity, and Cani et al. (2008) later 
showed that a high-fat, carbohydrate-free diet increases the flux of 
FITC-dextran from the gastrointestinal tract to the circulation. 
Obesity or dietary fat? 
Since gut barrier function was shown to be altered in both obesity and 
on a diabetogenic high-fat diet (Brun et al., 2007; Cani et al., 2008), it 
was still unclear whether barrier dysfunction is caused by obesity or a 
high-fat diet. A specific challenge in rodent obesity research is the diet-
induced obesity model, where animals become obese by eating a high-
fat diet (for review, see Hariri and Thibault, 2010). Although this model 
REVIEW OF THE LITERATURE 
- 31 - 
is very useful, it has not permitted the distinction between the effects 
of diet and expanding fat mass. Several studies over the past few years 
have been conducted in the field of dietary fat, obesity, barrier function 
and endotoxemia. These are summarized in Table 2. As barrier 
dysfunction is thought to be strongly linked with endotoxemia, studies 
with only plasma endotoxin analyses are also included. 
After the initial report by Brun et al. (2007), results on the link between 
obesity and barrier dysfunction have been unclear (Cani et al., 2008, 
2009; Suzuki and Hara, 2010; Haub et al., 2011). On the other hand, 
several reports have shown endotoxemia or increased gut permeability 
in designs that cannot distinguish between the effects of diet and 
obesity (Cani et al., 2007a, 2007b, 2008; Everard et al., 2012; Kim et 
al., 2012; Kirpich et al.,  2012; de La Serre et al., 2010; Laugerette et 
al., 2012; Serino et al., 2012). Only two studies have attempted to rule 
out the effect of obesity, and have reported an increased Cr-EDTA flux 
(Suzuki and Hara, 2010) or elevated serum endotoxins (Carvalho et al., 
2012) in animals fed with a high-fat diet. 
Another noteworthy matter is that although endotoxemia may reflect 
barrier dysfunction, the possible alterations in LPS clearance may bias 
results (Teixeira et al., 2012a), as discussed previously on page 24. It is 
thus important to conduct studies using direct markers of intestinal 
permeability, and to specifically compare studies using permeability 
probes. Only seven studies have used direct markers of permeability. 
Most of them show a permeability-increasing effect for diet-induced 
obesity in rats or a diabetogenic diet in mice (Cani et al., 2008; de La 
Serre et al., 2010; Serino et al., 2012), but the two studies on the 
effects of obesity, not dietary fat, have reported opposite results (Brun 
et al., 2007; Suzuki and Hara, 2010) – Suzuki and Hara (2010) did not 
see any difference in permeability by genetic obesity. In rats, dietary 
lard seems to impair gut barrier function (De La Serre et al., 2010; 
Suzuki and Hara, 2010), and in mice two studies using an extreme 
diabetogenic high-fat diet have showed increased dextran flux (Cani et 
al., 2008; Serino et al., 2012). Studies using this diabetogenic diet,
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however, have not been designed to study obesity and often do not 
report data for body weight. Thus, it cannot be ascertained that the 
reported effects are not attributable to the pathogenesis of diabetes. 
Fat quality has not been studied using permeability probes. However, 
recent findings reveal the complexity of the effects of different fatty 
acids on endotoxemia and metabolic inflammation. Various serum 
factors are involved in LPS-induced signaling (see 2.1.6), namely LBP 
and sCD14. The relative proportions of these serum factors seem to 
determine the magnitude of the inflammatory response that LPS 
induces. In an 8-week dietary intervention with milk fat, palm oil, 
rapeseed oil or sunflower oil, the mice receiving palm oil had the 
highest levels of plasma and adipose tissue inflammatory markers, but 
no change in plasma endotoxins (Laugerette et al.,  2012).  On  the  
contrary, mice receiving rapeseed oil had the highest levels of plasma 
endotoxins, but lowest level of the plasma inflammation marker 
interleukin-6. These converse inflammatory responses to endotoxemia 
were attributable to the level of soluble CD14, a plasma protein that 
binds  endotoxins  into  a  form  that  cannot  trigger  an  inflammatory  
response. The rapeseed oil diet resulted in a higher ratio of soluble 
CD14 to LPS compared to the palm oil diet. These results highlight the 
need to study plasma carrier proteins and inflammation in parallel 
with plasma endotoxins, in order to draw accurate conclusions of the 
effects of diet on pathophysiological mechanisms. 
To summarize, animal studies show increased 
intestinal permeability in models of diet-induced 
obesity, where the effects of obesity and a high-fat diet 
cannot be distinguished. Results on the independent 
effects of obesity are contradicting, and the effect of 
dietary fat, irrespective of obesity, has only been 
shown once in rats. Most dietary intervention studies 
in animals have utilized a high-fat diet with lard as the 
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principle fat source. Not many studies have addressed 
the matter of fat quality in gut barrier function. 
Human studies 
Human studies in the field of dietary fat, obesity and barrier function 
are scarce – only five studies have addressed this field. No difference in 
small  or  large  bowel  permeability  was  reported  in  a  small  pilot  study  
containing 13 obese and 11 control subjects (Brignardello et al., 2010). 
A 24h food intake recall revealed that there were no differences in 
dietary  fat  quantity  or  quality,  which  suggests  a  lack  of  effect  for  
obesity, not dietary fat. Another study on obese subjects demonstrated 
a borderline non-significant correlation for body weight and body mass 
index for lactulose/mannitol excretion ratio (Teixeira et al., 2012b). 
Dietary intake was not recorded. Interestingly, a study on obese 
patients with metabolic syndrome reported that the translocation of 
direct probes for both small and large intestine was increased in obese 
patients (Leber et al. 2012).  Again,  the  possible  role  of  dietary  fat  
cannot be excluded. 
The effects of dietary fat and fiber were studied in an elegant study by 
Pendyala et al. (2012), in which eight subjects were kept in metabolic 
wards for the duration of a cross-over intervention trial. A 1-month 
Western-style diet containing 40 E% fat (20.8 E% saturated fat) and 
only 12.5 g/day fiber increased endotoxemia by 71% compared to 
baseline, whereas a 1-month prudent diet containing 20 E% fat (5.8 
E% saturated) and 31 g/day fiber decreased endotoxemia by 31% 
compared to baseline. The trial periods were separated by a wash-out 
period of one month, and the energy contents of the diets were 
identical. The authors discussed that it is unclear whether the 
interventions affected intestinal permeability or merely changed the 
composition of gut microbiota (Pendyala et al., 2012). Finally, a 
Chinese cross-sectional study suggested that obesity was associated 
with a marker of endotoxemia, LBP, in healthy men (Sun et al., 2010). 
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To  summarize,  human  studies  do  not  clearly  
demonstrate a link between obesity or dietary fat and 
barrier dysfunction, although dietary changes appear to 
affect endotoxemia. In clinical settings it is more 
difficult  to  control  for  dietary  fat  intake,  which  may  
explain the small number of studies performed. 
2.2.3 Other dietary components 
Proteins and amino acids 
The perhaps most well-known amino acid impacting gut function is 
glutamine, the primary energy source for enterocytes (Blachier et al., 
2009). In a rat model of acute pancreatitis, this amino acid improves 
barrier function when given as a component of parenteral nutrition 
(Foitzik et al., 1997). Glutamine deprivation causes Caco-2 cell injury 
(Panigrahi et al., 1997), whereas glutamine supplementation protects 
Caco-2 cells from barrier dysfunction induced by media change (Li et 
al., 2003). In cancer patients, glutamine supplements may reduce 
barrier dysfunction induced by radiochemotherapy (Yoshida et al., 
1998). Several milk protein components have also been suggested to 
confer beneficial effects on the gut barrier, although mostly reported in 
cell models. These milk protein components include hydrolyzed casein, 
which decreases permeability in diabetes-prone rats (Visser et al., 
2010), a casein-derived peptide, Asn-Pro-Trp-Asp-Gln, which slightly 
but significantly increases TER and occludin levels in Caco-2 cells 
(Yasumatsu  and  Tanabe,  2010),  and  the  major  whey  protein  -
lactoglobulin, which increases TER when Caco-2-cell tight-junctions 
are destabilized by culturing in serum-free media (Hashimoto et al., 
1998). The arginine-rich nuclear protein protamine also improves 
barrier function in rat small intestine in vivo (Shi and Gisolfi, 1996). On 
the contrary, L-alanine and supraphysiological concentrations of 
tryptophan impair gut barrier in intestinal tissue of animals (Madara 
and Carlson, 1991; Sadowski and Meddings, 1993).
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Alcohol 
Alcoholic liver disease is well known to be characterized by 
gastrointestinal barrier dysfunction and endotoxemia in humans (for 
review, see Rao, 2009). It is clear that ethanol increases 
gastroduodenal permeability, but its role in barrier dysfunction in the 
distal intestine is unclear. Ethanol’s primary metabolite, acetaldehyde, 
impairs intestinal barrier function at much lower concentration than 
ethanol itself. Such small concentrations are detected in rat feces. It is 
thus believed that barrier dysfunction in the distal gut is acetaldehyde-
induced. Acetaldehyde accumulates in the colonic lumen, since the gut 
microbiota poorly metabolizes it further to acetate. 
Zinc, flavonoids and gliadin
Zinc,  flavonoids  and  gliadin  have  also  been  studied  in  terms  of  gut  
permeability, mostly in cell culture. Zinc has been proposed to have a 
role in barrier maintenance in cell cultures (Finamore et al., 2008). 
Also, the flavonoid quercetin increases TER and decreases probe flux in 
Caco-2 cells (Amasheh et al., 2008; Suzuki and Hara, 2009). Other 
flavonoids, epigallocatechin gallate in green tea (Watson et al., 2004) 
and genistein in soy (Schmitz et al., 1999), do not affect TER alone, but 
may be capable of preventing inflammation-induced barrier-disruption. 
Gliadin, the symptom-inflicting cereal component in celiac disease, 
decreases tissue resistance, causes reorganization of the cytoskeleton 
and compromises interactions of occludin and ZO-1 by inducing the 
production of barrier-toxic zonulin, as shown in patient tissue 
preparations and intestinal epithelial cell lines (Wang et al., 2000; 
Clemente et al., 2003; Drago et al., 2006). These events are probable 
reasons for barrier impairment by gliadin in celiac disease. 
2.2.4 Other factors 
Age
Intestinal permeability varies during the human lifespan. Immediately 
after birth, the intestinal barrier is immature and highly permeable to 
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macromolecules, but begins its rapid maturation once oral feeding is 
started (Weaver et al., 1984). This happens much faster in neonates 
receiving human milk compared to formula-fed infants (Taylor et al., 
2009). In the elderly, intestinal permeability does not seem to be 
changed (Saweirs et al., 1985; Riordan et al., 1997). 
Psychiatric stress 
Because early life stress is related to later onset of irritable bowel 
syndrome in humans, the maternal separation rat model has become a 
popular tool for irritable bowel syndrome investigation (for review, see 
O’Mahony et al., 2011). Maternally separated rats have been 
demonstrated to show increased permeability of the colon (Gareau et 
al., 2007) and barrier dysfunction induced by water avoidance stress 
(Söderholm et al.,  2002).  A  role  for  the  hypothalamus-derived  
corticotrophin-releasing hormone and the neural muscarinic and 
nicotinic receptors were suggested by these reports. The gut-brain axis 
is bidirectional: psychological stress alters gastrointestinal function, 
and inflammation of the gastrointestinal tract sends signals to the 
brain  via  the  vagus  nerve  or  a  humoral  pathway  (O’Mahony  et al., 
2011). The brain thus seems to have an important role in mediating 
gut function and barrier integrity.
Nonsteroidal anti-inflammatory drugs 
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as acetyl salicylic 
acid  and  ibuprofein  impair  the  gut  barrier  and  may  even  cause  
ulcerations and perforation, accounting for the gastrointestinal side-
effects of these drugs (for review, see Tachecí et al., 2010). The drug 
may damage the epithelium several times: first locally upon 
administration, then systemically once absorbed, and again locally if 
the drug is eliminated with bile. Systemically, NSAIDs inhibit the 
cyclooxygenase enzyme, which produces barrier-protective 
prostaglandins. Locally, NSAIDs disturb mitochondrial energy 
metabolism and may induce nitric oxide release, which both contribute 
to gut barrier impairment in the rat.
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Pathogens 
The intestinal lumen is home to several commensal bacteria. Some 
strains of microbes, however, are pathogenic and may impair intestinal 
barrier function in preclinical studies by the disruption of tight-
junctions and initiation of inflammatory cascades (for review, see 
Guttman and Finlay, 2009). These pathogens include bacteria such as 
Escherichia coli, Salmonella, Shigella flexneri and the common cause of 
food poisoning, Clostridium perfringens, most of which attack the cell 
using effector proteins or enterotoxins. The viruses hepatitis C, the 
respiratory and gastrointestinal pathogen reovirus, and the common 
cause of viral gastroenteritis rotavirus, usually specifically target tight-
junction proteins. In contrast, coxsackieviruses and adenoviruses use 
the coxsackie virus and adenovirus receptor for internalization and 
breakdown of the epithelial barrier. Interestingly, Vibrio cholerae has 
been discovered to use a bacterial surface protein, zonula occludens 
toxin, which increases probe flux and reduces TER in rabbit small 
intestine, but not in colon (Fasano et al., 1991, 1997).
Intestinal ischemia and radiation 
Gut barrier function is impaired by several acute threats to the body, 
some of which increase the risk of sepsis. These include acute 
pancreatitis (for review, see Andersson and Wang, 1999), surgery 
(Roumen et al., 1993; Bölke et al., 2001) and burns (for review, see 
Magnotti and Deitch, 2005), which are all characterized by intestinal 
ischemia in human subjects. Ischemia leads to increased intestinal 
permeability, which precedes sepsis  (for review, see Kong et al., 1998). 
Another  type  of  trauma to  the  gut  is  caused  by  radiation,  which  also  
impairs human gut barrier function (for review, see MacNaughton, 
2000). Evidence from animal studies shows that this may occur even 
before cell cycle arrest and impaired cell renewal. 
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2.3 Luminal bile acids 
2.3.1 Synthesis, transformation and absorption 
Bile acid synthesis and regulation of the bile acid pool 
Bile acids are synthesized from cholesterol in liver hepatocytes. The 
structures and synthesis of the most important bile acids are shown in 
Figure 3. Most bile acids, 75%, are synthesized by the classic or 
neutral  pathway,  in  which  the  rate-limiting  enzyme  is  the  CYP7A1,  
which adds an -hydroxyl group to carbon 7 in the sterol structure (for 
review, see Lefebvre et al., 2009). The human liver synthesizes two 
primary bile acids: cholic acid and chenodeoxycholic acid (CDCA) (for 
review, see Houten and Auwerx, 2008). In addition to these, the rodent 
liver produces a third species of primary bile acids, the muricholic 
acids, of which -muricholic acid (3,6,7) is most prominent. The 
other stereoisomers are -muricholic acid (3,6,7) and -muricholic 
acid (3,6,7). In rat liver, CDCA is metabolized into -muricholic 
acid and, via a ketone intermediate, into -muricholic acid (Botham 
and Boyd, 1983). Bile acids are secreted into bile as glycine and 
taurine conjugates, and stored in the gall bladder (for review, see 
Ridlon et al., 2006). Upon fat ingestion, cholecystokinin stimulates 
contractions of the gall bladder and bile flow to the duodenum. 
The bile acid pool is regulated by Farnesoid X receptor (FXR), which is 
activated by bile acids in both the intestine and the liver (for review, 
see  Chiang,  2009).  In  the  intestine  of  mice,  but  not  humans,  FXR  
induces the expression of the apical sodium-dependent bile acid 
transporter (ASBT). The lack of ASBT causes bile acid malabsorption. 
FXR also upregulates the ileal bile acid binding protein (IBABP) and 
fibroblast growth factor 19 (FGF19), which signals form the intestine to 
the liver to downregulate CYP7A1, the key enzyme in bile acid 
synthesis. FXR thus has an undeniable role in bile acid traffic in the 
intestine, mainly by increasing the reuptake of bile acids. In the liver 
its role is the opposite - it downregulates CYP7A1 and bile acid 
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synthesis via FGF19- and small heterodimer partner (SHP)-dependent 
pathways. FXR plays a critical role in the coordination of bile acid 
homeostasis. An unbalance in this homeostasis may lead to bile acid -
related diseases such as cholestasis, where bile acids accumulate in 
the liver causing damage to liver cells. Interestingly, bile acids are also 
involved in metabolic regulation (for review, see Prawitt et al., 2011) – 
bile acid sequestrants, such as cholestyramine, improve glycemic 
control in type 2 diabetic patients. The effects on glucose metabolism 
could  be  mediated  through  the  bile  acid  receptor  FXR,  which  guards  
liver glucose production. Another bile acid receptor, TGR-5, is 
suspected to take part in energy metabolism, possibly affecting weight 
gain in animals.
Modification of bile acids by intestinal microbiota 
Bile acids are very efficiently absorbed from the ileum and transported 
to the liver for reuse (Houten and Auwerx, 2008). This cycle is called 
the enterohepatic circulation. However, a small number of bile acids 
flow to the large intestine, where the bile salt hydrolases of gut 
microbes cleave them into their deconjugated form (Ridlon et al., 2006). 
Deconjugated bile acids are much more hydrophobic and on-go passive 
absorption from the colon. 
Gut microbes contain enzymes capable of oxidation and epimerization 
of bile acids (Ridlon et al., 2006). The most important of these is the 
	-hydroxylase, which produces the secondary bile acids deoxycholic 
acid (DCA) and lithocholic acid from their primary forms cholic acid 
and CDCA. This pathway is estimated to be found only in 0.0001% of 
colonic flora, in species of the Clostridium genus (Lefebvre et al., 2009). 
Human liver is unable to 7-hydroxylate the secondary bile acids back 
into their respective primary forms (Ridlon et al., 2006). Thus, DCA 
accumulates in the bile acid pool. Lithocholic acid is sulphated and 
lost in feces, and does not accumulate in the enterohepatic circulation. 
In rodents, the secondary bile acids are rehydroxylated by the liver and 
are not present in primary bile (Lefebvre et al., 2009). 
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Figure 3. Synthesis and metabolism of the most important bile acids. Dashed lines 
represent intermediate metabolites. The higher the hydrophobicity index (HIx), the 
more hydrophobic the structure is. 
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Ursodeoxycholic acid (UDCA) is one of the most hydrophilic bile acids. 
It comprises only two per cent of both biliary and fecal bile acids in 
humans (Ridlon et al., 2006). In bears it is one of the main bile acids 
(Houten and Auwerx, 2008), hence the name “urso”. Because the 
enzymes producing UDCA are unelucidated, it is unclear whether this 
bile acid is solely produced by gut microbiota, or if liver may contribute 
to its synthesis. UDCA is a 7-hydroxy epimer of CDCA, which also 
appears to be its precursor – the synthesis of UDCA is inducible by 
administration of CDCA (Salen et al., 1974). Furthermore, 
intravenously injected radiolabeled CDCA results in the redistribution 
of the label between CDCA and UDCA, which provides evidence that 
CDCA is transformed into ursodeoxycholic acid via 7-ketolithocholic 
acid (Salen et al., 1974). The bacterial species metabolizing CDCA to 7-
ketolithocholic acid were only recently elucidated (Fukiya et al., 2009). 
UDCA is sometimes called a tertiary bile acid, since it is not directly 
synthesized from the primary bile acids. 
2.3.2 How does diet modulate the luminal bile acid pool? 
There are several ways in which diet may affect the luminal bile acid 
pool. The most evident modifications are in the concentration and daily 
excretion of bile acids. Although useful, these parameters give only a 
rough estimate of how luminal bile acids could affect the 
gastrointestinal tract. The bile acid pool comprises several different bile 
acid structures that vary for example in hydrophobicity (Heuman, 
1989) and their ability to bind receptor molecules (Lefebvre et al., 
2009). It is then important to not only study the quantity, but also the 
quality of luminal bile acids. Furthermore, the gut lumen contains 
agents such as fibers that bind bile acids (Huang et al., 1978), possibly 
into a non-toxic form. If the bias caused by these agents cannot be 
ruled out in a study design, the cytotoxicity of fecal water (the aqueous 
phase in feces) should also be analyzed. 
REVIEW OF THE LITERATURE 
- 44 - 
Dietary fat 
An  early  report  in  the  70’s  concluded  that  increasing  fat  intake  
resulted in higher bile acid excretion in feces (Reddy et al., 1977). 
Similar results were later obtained in a population study (Reddy, 
1981), a controlled clinical trial (Cummings et al.,  1978)  and in  mice  
(Bianchini et al.,  1989).  Unsaturated  corn  oil  has  been  shown  to  
increase bile acid excretion compared to saturated cocoa butter 
(Connor et al., 1969). It was hypothesized that the bile acid excretion 
promoted by unsaturated fat is related to the serum cholesterol -
lowering effect of the same fatty acids. However, Reddy et al. (1977) 
noted no such effect for fat quality (corn oil or lard).   
Fat  quality,  in  humans  and  monkeys,  does  not  seem  to  affect  bile  
composition in the gallbladder (Tanaka et al., 1976; Scobey et al.,
1992; Yago et al., 2005). It may, however, affect the profile of bile acids 
in feces (Reddy et al., 1977, Sato et al. 1987; Monsma et al., 1996; 
Reddy et al., 1996). To compare results from the published papers in 
the present review, a hydrophobicity index was calculated from the 
data given by these reports. The index was calculated as a percentage-
weighted mean of hydrophobicities, as previously reported by Heuman 
(1989). Reddy et al.  (1996)  did  not  report  values  for  UDCA,  thus  the  
indices  for  that  study  were  calculated  without  UDCA.  A  high  
hydrophobicity index reflects a high content of secondary bile acids, 
which are potentially harmful to the intestinal mucosa (Reddy, 1981). 
The calculated indices are reviewed in Table 3. 
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Table 3. Effect of fat quality on fecal bile acid hydrophobicity in rats.
Total dietary 
fat content 
(w/w) 
Fat type Hydrophobicity index Reference 
5% 
or 
20% 
5% corn oil 0.464
Reddy et al. 1977 
5% lard 0.482
20% corn oil 0.601
20% lard 0.650
20% 
Corn oil 0.719
Sato et al. 1987 
Rapeseed oil 0.627
Sesame oil 0.608
Soybean oil 0.299
Pork lard 0.797
Beef tallow 0.755
16% 
Corn oil 0.597
Monsma et al. 1996 
Pork lard 0.462
Beef tallow 0.265
Cocoa butter 0.235
5% 
or 
23.5% 
Low fat corn oil 0.560
Reddy et al. 1996 High-fat corn oil 0.657
High-fat fish oil 0.500
The percentage-weighted hydrophobicity index (HIx) was calculated from data provided 
by the references using the hydrophobicities published by Heuman 1989 for 
lithocholic acid, deoxycholic acid, chenodeoxycholic acid, cholic acid, ursodeoxycholic 
acid  and  -muricholic  acid.  As  Reddy  et al. (1996) did not provide data for 
ursodeoxycholic acid, it was not included in the calculations for that study. 
Data of the effect of fat quality on fecal bile acid hydrophobicity is 
controversial. According to data by Reddy et al. (1977) and Sato et al.
(1987), saturated fat feeding increased the hydrophobicity index of 
feces. In contrast, Monsma et al. (1996) reported a lower 
hydrophobicity index after saturated fat feeding. Data from Reddy et al.
(1977; 1996) suggest that increased dietary fat increases fecal bile acid 
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hydrophobicity, while a high-fat fish oil diet did not affect 
hydrophobicity compared to the low-fat control. Without raw data and 
statistical analysis, these values should be reviewed only with caution 
and definite conclusions should not be drawn. 
Dietary fat quality may also affect concentration of bile acids in fecal 
water. In a study by Lapré et al. (1993), rats fed with palm oil or milk 
fat excreted more bile acids and had a higher bile acid concentration in 
fecal water compared to rats fed with corn oil. Fecal water cytotoxicity 
was highest in the palm oil group. 
To summarize, data on how dietary fat quality affects 
bile excretion are somewhat controversial. Increasing 
fat quantity results in higher bile acid excretion. The 
effect of fat quality on bile acid profile, however, is still 
debated. 
Cholesterol 
In studies investigating the effects of animal fat and vegetable fat on 
bile acid excretion, the diet high in animal fat is also high in 
cholesterol. This does not, however, seem to confound the data since 
even a 30-fold increase in dietary cholesterol  has no significant effect 
on fecal bile acid concentration in humans (Wilson and Lindsey, 1965). 
Excess cholesterol is mainly excreted as neutral sterols, not by 
conversion to bile acids (Quintão et al., 1971).  
Dietary fiber 
The main action of dietary fiber on the luminal bile acid pool is its 
diluting effect. Bile acid excretion was investigated in two populations, 
Kuopio (Finland) and New York,  with an equal fat  and protein intake,  
but  with  a  3-fold  higher  fiber  intake  in  Kuopio  (Reddy  et al., 1978). 
Daily excretion of secondary bile acids was not altered, perhaps 
because  of  equal  fat  intake  in  the  two  study  populations.  The  
concentration of those bile acids, however, was decreased in the 
Kuopio population. Dietary fiber is thus associated with increased stool 
REVIEW OF THE LITERATURE 
- 47 - 
bulk and decreased fecal bile acid concentration, suggesting a dilutive 
effect for secondary bile acids. In a controlled trial of 34 men, a high-
fiber diet containing different sources of soluble and insoluble fiber was 
compared to a low-fiber diet with similar fat content (Kesäniemi et al.,
1990). The high-fiber diet increased bile acid excretion, when 
calculated per day. This supports the hypothesis that fiber binds 
luminal bile acids, enhancing excretion. The quality of dietary fiber 
may affect its impact on bile acid excretion in humans and animals (for 
review, see Huang et al., 1978). Hemicellulose and pectin bind to bile 
acids and may increase their excretion which is proposedly 
accompanied by a decrease in serum cholesterol. In rats and hamsters, 
inulin, beta-cyclodextrin and psyllium enhance bile acid excretion, 
whereas guar gum and pectin have no effect (Levrat et al., 1994; 
Trautwein et al., 1998a, 1998b). Furthermore, fiber-rich food items 
may induce changes in bile  acid profile.  Bran feeding may reduce 7-
dehydroxylation of bile acid into their secondary forms, although not 
all studies support this result (Huang et al., 1978). There is also some 
evidence that cellulose, pectin, konjac glucomannan and inulin reduce 
fecal water concentrations of secondary bile acids and its cytotoxicity 
to Caco-2 cells (Chen et al., 2010). The effects of different fibers on 
luminal bile acid profile and cytotoxicity in vivo have not been studied. 
Other dietary ingredients 
Although animal products alter bile excretion, it seems to be the fat, 
not the protein that is effective - animal proteins have no effect on bile 
acid excretion (for review, see Reddy, 1981).
Dietary calcium has been suggested to protect from colonic cancer by 
precipitating toxic bile acids in the gut lumen. In a human placebo-
controlled trial, high calcium intake decreased the concentration of 
secondary bile acids in fecal water and reduced fecal water cytotoxicity 
(Govers et al., 1996). The daily output of bile acids was increased, 
which also suggests bile acid binding by calcium. Very similar results 
have been obtained in rats: Calcium phosphate supplementation 
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increased fecal bile acid excretion, but decreased fecal water 
cytotoxicity and concentration of bile acids (Lapré et al., 1993). Another 
rat study with lower dietary calcium levels has shown contrasting 
results (Lupton et al., 1994); increasing calcium phosphate intake 
reduced the excretion of total bile acids, while increasing fecal fat 
excretion. Fecal water was not analyzed for bile acids or cytotoxicity. A 
more recent human study shows that calcium increases excretion of 
bile acids, but has no effect on fecal water genotoxicity (Ditscheid et al., 
2009). There is, therefore, no consensus on whether calcium is able to 
precipitate luminal bile acids into a less cytotoxic form. 
2.3.3 Bile acids and epithelial permeability 
The earliest study on the effects of bile acids on intestinal permeability 
was published in 1972, but reported no difference in mucosal 
permeability to 14C-thiourea (Sladen and Harries, 1972). Later studies 
with other molecular probes mostly disagree. Due to the surfactant 
effect of bile acids, it was no surprise that unconjugated bile acids, 
especially DCA and CDCA, reversibly increase intestinal permeability to 
various probes at 1-21 mM concentrations in the rat (Fihn et al., 2003; 
Goerg et al., 1980, 1983; Gyory and Chang, 1983; Sun et al., 2004a, 
2004b), the rabbit (Chadwick et al., 1979; Fasano et al., 1990) and the 
pig (Argenzio and Whipp, 1983; Henrikson et al., 1989), with 
contrasting results on CDCA (Hollander et al., 1989). In human 
biopsies of sigmoid colon, 1 mM CDCA or 0.5-1 mM DCA increased 
permeability to Cr-EDTA, but translocation of horseraddish peroxidase 
was unaltered (Münch et al., 2007). Later the same group observed 
that colonic biopsies from colitis patients in remission responded to 
100 μM DCA or CDCA by an increased translocation of E. coli bacteria, 
but  without  any  change  in  TER  (Münch  et al., 2011). In human 
subjects in vivo,  a  750  mg  bolus  of  CDCA  increased  
lactulose/rhamnose ratio indicating an increased intestinal 
permeability (Van Nieuwenhoven et al., 1999). The barrier disrupting 
effect of bile acids, especially DCA and CDCA is thus well shown at 
various concentrations ranging between 0.5-21 mM. 
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Comparisons of bile acid structures in their potency to impair barrier 
function have mainly been studied in the Caco-2 cell model. In this cell 
model, the applied concentrations, 50-250 μM, are much smaller than 
for whole tissue. At 200 μM, all bile acids irrespective of 
hydrophobicity, seem to decrease TER (Araki et al., 2005), but at 50 μM 
some differences between bile acid species were seen: cholic acid, 
CDCA  and  DCA  increased  dextran  flux,  but  UDCA  had  no  effect  
(Raimondi et al., 2008). Hughes et al. (2008) have also shown a clear 
barrier-disruption by the secondary bile acids DCA and lithocholic 
acid, whereas data for cholic acid and CDCA are not as consistent. In 
rabbit colon, only DCA and CDCA increased permeability at 5 mM, 
whereas cholic acid and ursodeoxycholic acid did not (Chadwick et al., 
1979). 
Translocation pathway activation has been investigated by a mixture of 
cholic acid, DCA and taurocholic acid at equimolar concentrations 
(Catalioto et al.,  2008).  The  mixture  was  applied  onto  Caco-2  cells  at  
concentrations ranging between 0.5-4.5 mM, and three markers of 
permeability were used: lucifer yellow for paracellular transport, 
propranolol for transcellular transport and phenylalanine for active 
transport.  The  bile  acid  mixture  was  shown  to  upregulate  the  
paracellular pathway only. 
There are some indications of the mechanism of bile acid -induced 
barrier dysfunction. Whereas some studies have indicated an 
important role for the enteric nervous system (Fihn et al., 2003; Sun et 
al., 2003, 2004a) and nitric oxide (Sun et al.,  2004b)  in  bile  acid  -
induced barrier dysfunction in rat in vivo, cell studies have investigated 
the direct effects of bile acids on the epithelial layer. In Caco-2 cells, 
barrier disruption has been suggested to be mediated through 
production of reactive oxygen species (Araki et al., 2005) or epithelial 
growth factor receptor activation and occludin dephosphorylation and 
rearrangement (Raimondi et al., 2008), but not via changes in occludin 
content (Hughes et al., 2008). 
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Increased bile flow has been proposed as a mechanism for barrier 
dysfunction in high-fat feeding (Suzuki and Hara, 2010). However, the 
group could show increased permeability in Caco-2 cells only at a high 
concentration of gallbladder bile. The effects of different luminal bile 
acids, also colonic bile acids, and the possible alterations of bile acid 
profile  in  high-fat  feeding  and  barrier  dysfunction  were  not  
investigated. 
To summarize, the concept of individual bile acids 
increasing epithelial permeability is old, but little is 
still known of the effects of different bile acid 
structures and their mechanisms of action in intact 
tissue. Data comparing the effects of different bile 
acids are limited to cell studies, and an approach to 
study the possible barrier-disrupting effects of 
alterations of the entire bile acid pool is still missing. 
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3 AIMS OF THE STUDY 
Impaired gut barrier function predisposes to several inflammation-
related pathologies, such as inflammatory bowel diseases and fatty 
liver disease, which are proposed to develop when increased gut 
permeability allows leakage of endotoxins into circulation. In this 
study, the possible link between dietary fat and obesity, bile acids and 
barrier dysfunction was investigated in mouse models of diet-induced 
obesity and genetic obesity, as well as in vitro.
The specific aims were: 
i. To study whether barrier dysfunction is caused by obesity or 
dietary fat only, using diet-induced obese mice on a high-fat diet 
and genetically obese mice on a normal chow diet. (Studies I and 
II)
ii. To investigate whether dietary fat quantity or quality, or obesity 
as such, affect luminal bile acid profile and hydrophobicity. 
(Studies I, II and IV) 
iii. To define the possible role of hydrophobicity/hydrophilicity of 
bile acids in altering intestinal permeability using tissue 
preparations in an Ussing chamber and a feeding trial in mice. 
(Studies I and III) 
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4 MATERIALS AND METHODS 
4.1 Experimental animals and study designs 
All animals were obtained from Charles River: mice of the C57Bl/6J 
strain (Studies I-IV; Sulzfeld, Germany) and of the ob/ob strain (Study 
II; Calco, Italy). Mice were acclimatized for one week prior to 
experiments. They were housed in a 12 h/12 h light/dark environment 
with food and water ad libitum. Animal experiments were approved by 
the National Animal Experiment Board of Finland (ESAVI-2010-
03684/Ym-23 and ESAVI-6806-04.10.03-2011). Main research 
questions, mouse strains and diets for the individual studies are 
summarized in Table 4. 
In Study I mice were on a low-fat control diet or a high-fat diet for 15 
weeks until intestinal permeability was measured from tissue segments 
in the Ussing chamber with 4 kDa FITC dextran. Fecal samples for bile 
acid analysis were collected at week 13. 
In Study II fecal samples from ten 13-week-old C57Bl/6J mice and 
from seven ob/ob mice of the same age and background were collected 
for bile acid analysis. Mice were euthanized at week 15 for sample 
collection and measurement of intestinal permeability in the Ussing 
chamber with 4 kDa FITC dextran. 
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Study III included in vitro experiments, where DCA and/or UDCA were 
incubated with tissue preparations in the Ussing chamber before 
measurement of intestinal permeability (designs described in detail on 
page 57). Also, a 10-week DCA feeding experiment in vivo was included 
in  this  study.  In  the  feeding  trial,  mice  were  divided  into  two  groups:  
control and control diet with 0.2% DCA. Since the mice receiving DCA 
lost weight during the first week of the experiment, the dose was 
halved to 0.1%. Mice were euthanized at two time points: week 5 (n = 
6+6) and week 10 (n = 6+6). Intestinal permeability was measured in
vivo at the time of euthanasia. 
In Study IV mice were divided into the following four groups: 
- Control:   control diet, no colitis 
- DSS control:  control diet, DSS colitis 
- Lard DSS:  high-lard diet, DSS colitis 
- Fish oil DSS:  high-fish oil diet, DSS colitis 
DSS colitis was induced with dextran sulphate sodium (MP 
Biomedicals, Santa Ana, CA, USA) as a 5% solution in drinking water 
for two days, followed by two days of tap water. The fat sources of the 
study diets were as follows: 
- Control diet, 10 E% fat: 5.5 E% soy oil, 4.5 E% lard 
- Lard diet, 60 E% fat: 5.5 E% soy oil, 54.5 E% lard 
- Fish oil diet, 60 E% fat: 5.5 E% soy oil, 27.2 E% lard, 
27.2 E% menhaden oil 
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For the fish oil diet, half of the fat not accounting for soy oil was lard 
and half menhaden oil, to be able to pellet the diet. Feces were 
collected in metabolic cages before colitis induction. At the end of the 
study, intestinal permeability was measured in vivo and ex vivo with 
fluorescein in an Ussing chamber. Jejunum and colon were collected 
for  further  analysis  of  TNF-alpha.  The  study  design  is  illustrated  in  
Figure 4.
Figure 4. The design of Study IV. Animals were fed with low-fat and 
high-fat (lard/fish oil) diets for the entire duration of the study. DSS 
colitis was induced during the final four days. The round-headed arrow 
represents the time point where fecal samples were collected in 
metabolic cages.
4.2 Tissue collection 
Mice  were  euthanized  with  a  gas  mixture  of  CO2 (70%)  and O2 (30%) 
(AGA, Riihimäki, Finland) and cervical dislocation (Studies I-II) or 
decapitation, in the experiments with terminal blood sampling (Studies 
II-IV). 
Fresh segments of intestine for Ussing chamber experiments were 
collected by carefully removing mesenteric fat. No muscle layers were 
removed for the Ussing chamber experiments. The first two segments 
of the small intestine after the pylorus were determined to be 
duodenum and the last two segments ileum. Jejunum was collected by 
folding the small intestine into a loop with the proximal duodenum and 
ileum side-by-side, and dissecting the two middle-most segments for 
the Ussing chamber. The two most proximal segments of the colon 
were called proximal colon and the two most distal segments distal 
colon, however, the colon is only long enough for three Ussing chamber 
segments. In Studies I, II and III, segments from each area of the 
intestine were collected in duplicate. Since only four Ussing chambers 
were available for Study I, permeability could only be measured from 
Dietary intervention
DSS colitis
Week 1 Week 2 Week 3 Week 4
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two intestinal locations from each mouse. Segments from the following 
locations were collected: 
- Study I: duodenum, jejunum, ileum and proximal colon 
- Study II: jejunum and distal colon 
- Study III: jejunum and distal colon 
- Study IV: proximal colon 
Tissue specimens for protein or gene expression analysis were snap-
frozen in liquid nitrogen and stored at -80ºC. 
4.3 Ussing chamber experiments 
Intestinal segments were opened along the mesenteric border, pinned 
onto 0.3cm2 sliders and mounted into an EasyMount Ussing chamber 
system with a voltage-clamp apparatus (Physiologic Instruments, CA, 
USA). Tissues were surrounded by 5 ml Ringer solution on each side 
(120 mM NaCl, 5 mM KCl, 25 mM NaHCO3, 1.8 mM Na2HPO4, 0.2 mM 
NaH2PO4, 1.25 mM CaCl2,  1  mM MgSO4,  10  mM glucose)  and water-
jacketed to 37ºC. The system was carbonated with a carbogen (95% O2 , 
5% CO2, AGA, Riihimäki, Finland) gas flow to a pH of 7.4. The system 
was  allowed  to  equilibrate  for  a  minimum  of  10  min  before  
experiments. 
For measurement of intestinal permeability, 4 kDa FITC-dextran (TdB 
Cons,  Uppsala,  Sweden)  was  added  to  the  luminal  side  to  a  final  
concentration  of  2.2  mg/ml  (Studies  I,  II  and  III),  or  for  fluorescein  
(Study IV) measurements to a concentration of 2 μg/ml. Serosal 
samples were taken at 45 min. Serosal fluorescence was detected with 
a Wallac Victor2 1420 Multilabel counter (Perkin Elmer, Waltham, MA, 
USA) using an excitation/emission of 493/518 nm. Results were 
obtained by comparing serosal fluorescence to luminal fluorescence 
and expressed as per mille (1/1000) translocated dextran. Tissue 
resistance and short-circuit current were monitored throughout the 
experiments. 
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4.4 In vitro bile acid experiments 
The barrier-altering effects of two bile acids different in hydrophobicity, 
DCA and UDCA, were investigated in vitro in an Ussing chamber (study 
III). The designs of the in vitro studies are presented below. Both 
jejunum and colon were used in designs 1-3. 
Design 1: Dose-dependence studies 
The effects of sodium deoxycholic acid (Sigma-Aldrich, St. Louis, MO, 
USA) and ursodeoxycholic acid (Leiras Ltd, Helsinki, Finland) on 
barrier function were tested with five concentrations for each bile acid: 
0, 0.03, 0.3, 1 and 3 mM. Bile acids had no effect on the pH of Ringer 
solutions, nor did they induce cell death, measured as lactate 
dehydrogenase activity, which could have caused misinterpretations of 
the  data.  Intestinal  permeability  was  measured  with  4  kDa  FITC  
dextran.  Using  a  larger  molecular  weight  dextran  (20  kDa  FITC  
dextran, TdB Cons), six experiments were conducted with the 
concentrations 0, 1 and 3 mM for only DCA. The bile acid -induced 
changes in tissue resistance were calculated from all experiments 
containing 0, 1 and 3 mM DCA. 
Design 2: UDCA in DCA-induced barrier dysfunction 
To test the possible protective effect of UDCA in DCA-induced barrier 
defect, luminal DCA (3 mM) was used with four different 
concentrations of UDCA: 0.1, 0.3, 0.6 and 1 mM. Permeability was 
measured with 4 kDa FITC dextran.
Design 3: Dexamethasone treatment 
To investigate whether the permeability-inducing effect of DCA is 
inflammation-dependent, we used 1 μM water soluble dexamethasone 
(D2915, Sigma-Aldrich) on the luminal side of the tissue segment. The 
drug was co-incubated with 3 mM DCA for 20 min before a wash and 
permeability measurements with 4 kDA FITC dextran.
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Design 4: LPS and intestinal permeability 
To test the hypothesis that LPS aggravates DCA-induced barrier 
dysfunction, but does not increase intestinal permeability alone, a 
barrier  defect  was  induced  with  3  mM DCA for  20  min.  The  bile  acid  
was washed from the chambers twice with Ringer solution before 
adding LPS from Escherichia coli O55:B5 (L2880, Sigma-Aldrich) at the 
concentrations 0.5, 1.5 and 4.5 μg/ml for 60 min. To test whether LPS 
has an effect on intestinal permeability independently of DCA, 0.5 and 
4.5 μg/ml LPS was incubated with segments preincubated with Ringer 
solution only. Similar experiments were performed with 1 and 5 μg/ml 
in colon segments from Wistar rats. Permeability was measured with 4 
kDa FITC dextran. 
Tissue preparation for protein analyses 
Distal colon was dissected from male and female 12-13-week-old 
C57Bl/6J mice (Charles River). The mice were euthanized with a gas 
mixture of 70% CO2 / 30% O2 (AGA) and cervical dislocation. The distal 
colon was cut into four segments, each of which were placed in one of 
four solutions:  1)  Ringer,  2)  Ringer with 3 mM DCA, 3)  Ringer with 3 
mM DCA and 0.3 mM UDCA, and 4)  Ringer with 3 mM DCA and 0.6 
mM UDCA. Segments were incubated for 20 min at 37°C, until  either 
snap-frozen  in  liquid  nitrogen  and  stored  in  -80°C  for  Western  blot  
analysis of COX-2, or fixed in 10% neutral buffered formaldehyde 
(Sigma-Aldrich) for 24-48 h and embedded in paraffin for 
immunohistochemistry or hematoxylin-eosin staining. 
4.5 Measurement of intestinal permeability in vivo 
Permeability of the whole intestine was measured in vivo in Studies III 
and IV. Mice were fasted overnight and gavaged with 500 mg/kg FITC 
dextran  (4000  Da;  TdB  Cons).  After  exactly  4  h  the  mouse  was  
euthanized and blood was collected by decapitation into an Eppendorf 
tube. Serum was separated by centrifugation (15 min, 1000 g) and 
diluted to 1/5 into phosphate-buffered saline. Fluorescence was 
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detected with a Wallac Victor2 1420 Multilabel counter (Perkin Elmer), 
using excitation/emission of 493/518 nm. 
4.6 Fecal bile acid analyses 
Feces were collected from each mouse in individual metabolic cages 
(Studies  I,  II  and  IV).  Feed  and  water  was  provided  ad libitum. Feces 
were carefully separated from all other material and frozen at -20ºC. 
Upon analysis, fecal samples were dried overnight with a nitrogen gas 
flow and pulverized. Bile acids were extracted and analyzed for all fecal 
bile acids by gas-liquid chromatography according to a previously 
described method (Grundy et al., 1965). Internal standards were run to 
identify isolithocholic acid, lithocholic acid, epideoxycholic acid, 
deoxycholic acid, chenodeoxycholic acid, cholic acid, -muricholic and 
ursodeoxycholic acid. The proportions of these bile acids were 
calculated as a percentage of total bile acids, both identified and 
unidentified. An index for fecal bile acid hydrophobicity was calculated 
(Studies II, IV and unpublished data from Study I) as a percentage-
weighted mean of the hydrophobicities of six bile acids – lithocholic 
acid, deoxycholic acid, chenodeoxycholic acid, cholic acid, 
ursodeoxycholic acid and -muricholic acid – according to a previous 
report (Heuman, 1989), using estimated values for lithocholic acid 
(1.13) and muricholic acid (-0.65). A value for daily bile acid excretion 
was calculated from bile acid concentrations and metabolic cage data 
for daily fecal excretion. 
4.7 Biochemical analyses 
Gene expression analyses (Study II) 
RNA was extracted from tissue with Trizol reagent. RNA was converted 
to cDNA with an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, 
USA) according to the manufacturer’s instructions, using 1μg of RNA in 
a reaction volume of 20μl. Reactions for quantitative polymerase chain 
reaction were run using TaqMan chemistry (Applied Biosystems, 
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Carlsbad, CA, USA) for FXR (Mm00436420_m1), and LBP 
(Mm00493139_m1). Gene expressions were normalized to beta-actin. 
Reactions were run on a CFX96 (Bio-Rad) in triplicate. Gene expression 
was  calculated  with  Bio-Rad  CFX  Manager  software  using  the  
normalized expression C(t) method. 
Western blot analysis (Study III) 
Western blot -analyses were performed using the following antibodies: 
mouse occludin 1:350 (33-1500, Invitrogen, Life Technologies, Paisley, 
United Kingdom), anti-mouse 1:200 (HAF007, R&D Systems, 
Minneapolis, MN, USA), rabbit -actin 1:300 (#4967S, Cell Signaling 
Technology, Danvers, MA, USA), anti-rabbit 1:500 (#170-6515, Bio-
Rad), goat COX-2 1:200 (sc-1747, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and anti-goat 1:2000 (sc-2020, Santa Cruz 
Biotechnology). Occludin was blotted from four tissue preparations per 
group, whereas COX-2 was blotted from seven tissue preparations per 
group. 
Immunohistochemistry (Study III) 
Immunohistochemistery was performed using the following antibodies: 
mouse anti-occludin (33-1500, Invitrogen), anti-mouse FITC (Fisher 
Scientific, Waltham, MA, USA). Nuclei were stained with 4’,6-diamino-
2-phenylindole (DAPI). 
Tissue TNF-alpha analysis (Study IV) 
Tissue TNF-alpha was quantified using tissue homogenates in a 
commercial enzyme-linked immunosorbent assay (ELISA) kit 
(RBMS607/2R, BioVendor, Brno, Czech Republic) in a single run (CV 
4.3%), and data were expressed as pg/mg protein.
Serological analyses 
In  Study  II,  serum  LBP  was  analysed  using  a  commercial  ELISA  for  
mouse LBP (HK205, Hycult biotech, Uden, The Netherlands) in a single 
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run (CV 3.6%). Serum cholesterol precursors desmosterol and 
lathosterol, which reflect whole body cholesterol synthesis, and 
cholestanol and campesterol, which reflect cholesterol absorption 
efficiency also in animal studies (Pirinen et al., 2010), were quantified 
with gas liquid chromatography on a 50-m long capillary column (Ultra 
2; Agilent Technologies; Wilmington, DE) using 5-cholestane as 
internal standard (Miettinen, 1988). The values are expressed as ratios 
to cholesterol of the same run (102 μg/mg cholesterol).
4.8 Scores for diarrhea and colonic inflammation 
In  Study  IV,  the  severity  of  DSS colitis  was  evaluated  during  the  last  
four days of the study with a subjective score for the severity of 
diarrhea in mice. The score was defined using the following five 
classes:  0  =  no  symptoms,  1  =  blood  at  rectal  area,  2  =  bloody  
excrement, 3 = massive bloody diarrhea, 4 = animal deceased. 
At euthanasia, the entire colon was dissected, opened and flushed free 
of intestinal contents. The preparation was pinned onto a silicon dish 
and photographed. Three experienced evaluators blindedly scored the 
samples for a general inflamed appearance using a VAS line (0-100). 
4.9 Data analysis 
All differences between groups were analyzed non-parametrically with 
Mann-Whitney U test. In the case of several groups, global differences 
were  first  analyzed  with  Kruskall-Wallis  test.  If  global  P  <  0.05,  
differences were analyzed with Mann-Whitney U test. 
Intestinal permeability could only be measured from two locations in 
each mouse. To correlate all bile acid analyses to intestinal 
permeability, an average of intestinal permeability in the two segments 
measured from each mouse was calculated and correlated to 
hydrophobicity index. All correlations were calculated as the non-
parametric Spearman’s rho. 
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For data on in vivo feeding of DCA, results were analyzed with a 2x2 
factorial test (Univariate analysis of variance), since the study 
contained two fixed factors: diet (control and DCA) and duration (5 and 
10 weeks). This test shows the independent effect of these two factors 
and any possible interaction. 
For  experiments  with  DCA  and  LPS  on  rat  intestine,  the  data  were  
analyzed by a professional statistician with the Generalized Estimating 
Equations  -method.  DCA+LPS  groups  were  compared  to  the  DCA  
control, and LPS groups were compared to Ringer only. For mouse 
tissue, differences for all pairs were analyzed with the non-parametric 
paired Wilcoxon test. 
Statistical analyses for all studies were performed with PASW Statistics 
version  18.0.2  (IBM,  Armonk,  NY  USA).  All  data  are  expressed  as  
median (interquartile range) unless otherwise stated, and all P-values 
are expressed two-sided. 
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5 RESULTS 
5.1 Body weight of mice in dietary interventions 
After a 15-week high-fat feeding (Study I), the high-fat mice weighed 
approximately double compared to control mice [50.5 g (47.2,51.6) for 
high-fat, 28.8 g (27.4, 30.3) for control, P < 0.001]. In Study II, 15-
week-old ob/ob mice were approximately the weight of the high-fat-fed 
mice [54.0 g (51.9, 54.7)], also double that of the wild-type mice [26.3 g 
(24.1, 28.5), P < 0.001). In the four-week feeding trial with a high-fat 
lard diet, high-fat lard-fish oil diet and a low-fat control diet (Study IV), 
high-fat groups weighed slightly more than the control groups at week 
three, the time of bile acid collection [25.4 g (23.7, 26.6) for control, 
29.2 g (27.2, 31.6) for lard, 28.6 g (27.4, 29.4) for fish oil, P < 0.01 for 
both high-fat vs. controls]. There was no difference in weight between 
the two high-fat groups (P = 0.24). 
5.2 Effects of dietary fat and obesity on gut barrier 
function
Dietary fat -induced obesity increased dextran translocation in jejunum 
and colon (Study I) 
High-fat-feeding increased intestinal permeability significantly in 
jejunum (median 0.334 per mille translocated dextran for control vs. 
RESULTS 
- 64 - 
0.393  for  high-fat,  P  =  0.03)  and  colon  (median  0.335  for  control  vs.  
0.433 for high-fat, P = 0.01), but not in duodenum (P = 0.33) or ileum 
(P = 0.69, Figure 5). 
Figure 5. The  effect  of  a  high-fat  diet  on  intestinal  permeability  in  
duodenum, jejunum, ileum and colon. Permeability was measured in an 
Ussing chamber. Boxplots show median with upper and lower 
quartiles. Whiskers show min and max with outliers (Tukey) expressed 
as black dots. * P < 0.05, NS = Non-significant. 
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Obesity had no effect on barrier function (Study II) 
There were no signs of altered permeability to FITC dextran in either 
jejunum  (P  =  0.93)  or  colon  (P  =  0.86)  in  obese  vs.  wild-type  mice  
(Figure 6). 
Liver LBP expression was measured as a marker of portal endotoxin. 
There was no difference in liver LBP expression between obese and 
wild-type mice [0.47 (0.41, 0.60) for obese, 0.53 (0.19, 0.84) for wild-
type, P = 0.70]. In contrast, serum LBP was increased 2.5-fold in obese 
mice vs. wild-type [30.5 μg/ml (24.8, 41.8) for obese, 11.4 μg/ml (8.8, 
16.3) for wild-type, P = 0.001].  
Figure 6. The effect of genetic obesity on permeability of jejunum and 
colon. Permeability was measured in an Ussing chamber. Boxplots 
show median with upper and lower quartiles. Whiskers show min and 
max. NS = Non-significant. 
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5.3 Effects of dietary fat and obesity on fecal bile 
acids 
Fecal bile acid excretion was increased by dietary lard, and even more 
by dietary fish oil (Studies I, II and IV) 
High-fat feeding increased fecal bile acid concentration 3.6-fold in a 15-
week feeding trial (Study I, Table 5). This was reflected as a statistically 
significant elevation of each bile acid concentration except 
isolithocholic acid and -muricholic acid. A non-significant tendency 
for a similar effect for lard feeding was seen in the much shorter, 3-
week  trial  (Study  IV,  Table  5).  Total  fecal  bile  acid  concentration  was  
nearly doubled by fish oil. The fish oil diet resulted in a significantly 
greater concentration of DCA and total bile acids in feces compared to 
lard-fed mice. 
In genetically obese mice, daily excretion of fecal bile acids was 
increased 36% compared to wild-type mice (3908 μg/day vs. 2870 
μg/day, P = 0.001), however, the concentration of total fecal bile acids 
was decreased by 33% (Study II, Table 5). The concentrations of cholic 
acid and -muricholic acid were decreased in obese mice, whereas the 
concentration of isolithocholic acid was increased (Table 5). There were 
no differences in other bile acids. The increased daily excretion of bile 
acids was not reflected in liver FXR expression, which was unchanged 
[relative expression 0.337 (0.177,1.000) for obese vs. 0.607 
(0.516,1.089) for wild-type, P = 0.42]. 
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Fecal bile acid hydrophobicity was increased by dietary lard and fish oil, 
but not by obesity (Studies I, II and IV) 
Dietary fat feeding (Studies I and IV) increased the fecal proportion of 
one  of  the  most  hydrophobic  bile  acids,  DCA,  whereas  obesity  alone  
had no effect (Study II) (Table 6). The proportion of -muricholic acid 
was decreased by both long-term dietary fat feeding and obesity, but 
not by short-term high-fat feeding. Neither obesity nor dietary fat 
affected UDCA, although obesity tended to increase its proportion in 
fecal bile acids 4.6-fold (P = 0.051). The proportion of isolithocholic acid 
was decreased by dietary fat, but increased by obesity. A similar trend 
was seen for CDCA. Conversely, the proportion of cholic acid was 
increased by dietary fat and decreased by obesity. 
The  ratio  of  UDCA  to  DCA  was  halved  by  both  high-fat  diets  in  even  
short-term feeding, but was not significantly affected by obesity, 
despite a 3.2-fold higher ratio compared to wild-type mice. Long-term 
feeding of dietary fat increased fecal bile acid hydrophobicity 2.7-fold (P 
= 0.004, Study I), and short-term 1.4-fold by lard and 2.0-fold by fish 
oil  (P = 0.027 and P = 0.003, respectively,  Study IV),  whereas obesity 
had no effect (P = 0.205) (Table 6). 
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5.4 Effects of fecal bile acids on gut barrier 
function and inflammation 
Fecal bile acid hydrophobicity was correlated with intestinal 
permeability (Study I and unpublished results) 
A value for total intestinal permeability was calculated as a mean 
permeability of the measured segments, because permeability could 
not be measured from all segments from all mice. Fecal bile acid 
hydrophobicity was correlated with total intestinal permeability so that 
those mice with a higher hydrophobicity index displayed higher probe 
permeability  ( =  0.75,  P  =  0.008;  Figure  7).  A  trend  for  a  similar  
positive correlation was noted in jejunum, ileum and colon, but not in 
duodenum (Figure 8). 
Figure 7. Correlation between total intestinal permeability and fecal 
bile acid hydrophobicity index. Each dot represents an individual 
animal. 
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Figure 8. Correlation between intestinal permeability of duodenum (A), 
jejunum (B), ileum (C) and colon (D) and fecal bile acid hydrophobicity 
index. Each dot represents an individual animal. 
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DCA impaired gut barrier function in vivo and dose-dependently in vitro 
(Study III) 
In a 10-week in vivo feeding trial, a diet containing 0.1% DCA impaired 
gut barrier function (factorial test, P for diet = 0.016, P for duration = 
0.27; Figure 9). In vitro, DCA increased intestinal permeability to 4 kDa 
FITC dextran dose-dependently in both jejunum and colon (Figure 10 
A-B). A significant barrier impairment was noted at concentrations that 
are found in feces of high-fat fed mice: 1 mM (1.8-fold increase in 
median in jejunum, 1.9-fold in colon) and 3 mM (2.2-fold increase in 
median in jejunum, 3.5-fold in colon), whereas no effect was seen at 
lower concentrations:  0.03 and 0.3 mM. Permeability to the larger 20 
kDa dextran was also increased by 3 mM DCA in colon (Figure 10 D), 
but not in jejunum (Figure 10 C). Tissue resistance was decreased by 
DCA in colon, but not in jejunum.  
Figure 9. Intestinal permeability after 5 or 10 weeks of dietary 
deoxycholic acid (DCA) feeding. Serum 4 kDa FITC dextran 
concentrations 4 h after dextran gavage. Boxplots show median with 
upper and lower quartiles. Whiskers show min and max. Results were 
analyzed with a factorial test. N = 5-6 per group. 
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Figure 10. Effect of deoxycholic acid (DCA) on the permeability of 4 (A-
B)  and 20 kDa FITC dextran (C-D)  in jejunum and colon preparations.  
Boxplots show median with upper and lower quartiles. Whiskers show 
min and max with outliers (Tukey) expressed as black dots. A and B: 0, 
0.3 and 3 mM: N = 12; 0.03 and 1 mM: N = 6. C and D: N = 6 per group. 
* P < 0.05, ** P < 0.01, *** P < 0.001, NS = Non-significant. 
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UDCA protected the gut from DCA-induced barrier dysfunction (Study III) 
UDCA did not affect permeability in either jejunum (global P = 0.10) or 
colon (global P = 0.75)  (Figure 11 A-B).  UDCA had no effect  on tissue 
resistance in either jejunum or colon (data not shown). 
UDCA protected colon against DCA-induced barrier dysfunction at 0.6 
mM (P < 0.05) with a more than 50% decrease in the median value of 
permeability, and there was a decreasing trend at concentrations 0.1 
mM and 0.3 mM (Figure 11 D). UDCA had no significant protective 
effect against DCA in jejunum (Figure 11 C). UDCA had no effect on the 
DCA-induced changes in tissue resistance (data not shown). 
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Figure 11. Effect of ursodeoxycholic acid (UDCA) on permeability of 
jejunal and colonic tissue preparations (A-B), and its interaction with 3 
mM deoxycholic acid (DCA) (C-D). Boxplots show median with upper 
and lower quartiles. Whiskers show min and max with outliers (Tukey) 
expressed as black dots. A and B: 0, 0.3 and 3 mM: N = 12; 0.03 an 1 
mM: N = 6. C and D: N = 20 for control and DCA only, N = 10 for groups 
with  DCA  +  UDCA.  *  P  <  0.05,  **  P  <  0.01,  ***  P  <  0.001,  NS  =  Non-
significant. 
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DCA disrupted colonic morphology, but not via inflammation (Study III) 
Epithelial morphology was dramatically altered by deoxycholic acid. 
Both hematoxylin-eosin staining and immunofluorescence staining for 
occludin revealed that the colonic epithelium was disrupted by 3 mM 
DCA. This effect was inhibited by 0.6 mM UDCA (Figure 12). Tissue 
disruption was not reflected as an elevated COX-2 content (P = 0.57, 
Figure 13), nor did dexamethasone treatment inhibit barrier 
impairment. 
Figure 12. Tissue morphological changes by deoxycholic acid (DCA) 
and DCA with ursodeoxycholic acid (UDCA). Slides were stained with 
hematoxylin-eosin (A) and occludin (B: 20x magnification, C: 40x 
magnification). Green shows occludin, blue shows DAPI staining.
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Figure 13. COX-2 content, as measured by Western blot after 
incubation in 3 mM deoxycholic acid (DCA). Boxplots show median with 
upper and lower quartiles. Whiskers show min and max with outliers 
(Tukey) expressed as black dots. N = 7 per group.
LPS may aggravate DCA-induced barrier dysfunction in colon (Study III)
LPS treatment seemed to aggravate DCA-induced barrier dysfunction 
by doubling permeability at a concentration of 4.5 μg/ml (P = 0.075, 
Figure 14 A). LPS had no effect on the permeability of intact intestinal 
tissue. Similar results were seen in rat colon (Figure 14 B). Median 
colonic permeability to dextran was slightly higher in both LPS+DCA 
groups compared to DCA only, and in a Generalized Estimated 
Equations analysis 5 μg/ml LPS with DCA tended to aggravate barrier 
dysfunction (P = 0.05). LPS had no effect on the permeability of intact 
rat intestine.
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Figure 14. Effect of LPS on DCA-induced barrier dysfunction in mouse 
(A) and rat (B) colon. Boxplots show median with upper and lower 
quartiles. Whiskers show min and max with outliers (Tukey) expressed 
as black dots. N = 7-24 per group. 
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5.5 Dietary fat and susceptibility to experimental 
colitis
Upon DSS administration (Study IV), mice in the DSS groups began to 
lose  weight  and  the  general  well-being  of  all  DSS  groups  was  greatly  
impaired compared to the healthy control  [Symptom score 0 (0,  0)  for 
Control, 7.0 (1.8, 10) for DSS-Control, 1.0 (0.0, 7.3) for DSS-Lard, 7.5 
(5.8,  9.0)  for  DSS-Fish  oil,  P  <  0.01  for  all  DSS  groups  vs.  healthy  
control]. However, there were marked differences between the DSS-
groups in symptom development. Whereas most DSS-Fish oil mice 
deceased after the second day of DSS administration and had severe 
bloody diarrhea, the DSS-Lard group seemed to have less bleeding 
than either of the other DSS groups (P = 0.03 DSS-Lard vs. DSS-Fish 
oil, P = 0.07 DSS-Lard vs. DSS-Control). These differences were also 
reflected in the large intestinal inflammation score [Score 4 (1.0, 5.5) 
for Control, 58 (41, 86) for DSS-Control, 27 (9.0, 79) for DSS-Lard], 
although only two DSS-Fish oil mice could be scored for large intestinal 
inflammation and were not included in the statistical analysis (values 
19 and 77). All DSS-groups scored higher than control mice (P < 0.05 
for all comparisons), and the gut inflammation score was, although 
non-significantly, halved in DSS-Lard mice compared to DSS-Control 
mice (P = 0.32). The symptom score AUC was significantly correlated 
with fecal bile acid hydrophobicity (Spearman’s rho 0.44, P = 0.026, N 
= 26), as well as with fecal DCA concentration (Spearman’s rho 0.39, P 
= 0.046, N = 26) in DSS mice. 
In intestinal TNF-, there were differences between groups in colon (P = 
0.001),  but  not  in  jejunum  (P  =  0.48).  Although  DSS  groups  had  
marked macroscopic inflammation, tissue levels of TNF- were lower in 
both DSS groups compared to healthy control  [78 pg/mg protein (69,  
87) for Control, 51 pg/mg protein (46, 53) for DSS-Control, 36 pg/mg 
protein (32, 41) for DSS-Lard, P < 0.01 for both comparisons]. As with 
inflammatory markers, intestinal permeability could only be measured 
from those mice that survived until the last day of the experiment. The 
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data concerning these markers could be biased by the missing 
individuals,  which may explain why no difference in permeability was 
caused by the DSS colitis model.
The main findings of this thesis are summarized in Table 7. 
Table 7. Summary of the main findings 
Study Result 
Do obesity and dietary fat impair gut barrier function? 
High-fat diet I 
Obesity II 
Do dietary fat, obesity, or dietary fish oil compared to 
lard, increase fecal bile acid hydrophobicity? 
High-fat diet I, IV 
Fish oil vs. Lard diet IV 
Obesity II 
Do specific bile acids different in hydrophobicity 
increase intestinal permeability? 
Deoxycholic acid (DCA) in vivo III 
DCA in vitro III 
Ursodeoxycholic acid (UDCA) in vitro III 
UDCA in DCA-induced barrier impairment III 
By which mechanisms do bile acids cause barrier
impairment? 
Increased COX-2 protein content III 
Histological disruption of tissue structure III 
Changes in occludin content or distribution III 
Do dietary fats increase susceptibility to DSS colitis? 
Dietary lard IV 
 Dietary fish oil IV 
Is fecal bile acid hydrophobicity associated with 
increased susceptibility to DSS colitis? IV 
Arrows indicate yes (), no () or contrary effect () in answer to the question 
stated. Diagonal arrows indicate statistically non-significant tendencies.  
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6 DISCUSSION 
Impaired barrier function allows the translocation of toxic substances 
from the gut lumen into the circulation. Some of these substances, i.e. 
endotoxins, may cause metabolic inflammation, which is a risk factor 
for cardiovascular disease and diabetes. This series of studies 
investigated the role of dietary fat and obesity in the pathogenesis of 
gut barrier dysfunction. Luminal bile acids and their properties were 
studied as a mechanism for barrier impairment.
6.1 Methodological aspects 
6.1.1 Methods for measuring intestinal permeability 
In this series of studies intestinal permeability was primarily measured 
as the translocation of fluorescent probes through intestinal 
preparations in an Ussing chamber and into serum in vivo. These are 
direct measures of intestinal permeability, and thus more reliable than 
the biochemical analysis of tight-junction proteins. 
According to the hypothesis, increased intestinal permeability enables 
the increased translocation of LPS, which causes systemic low-grade 
inflammation (Cani and Delzenne, 2009). A permeability probe in this 
setting should then preferably simulate the translocation of LPS. In the 
present set of experiments, intestinal permeability was measured with 
FITC-labeled dextran in two different sizes, 4 and 20 kDa, and 
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fluorescein (0.38 kDa). Whereas the smallest of these, fluorescein, 
likely translocates paracellularly from villous tips (Arrieta et al., 2006), 
the largest, 20 kDa FITC dextran, may translocate either 
transcellularly or paracellularly (see chapter 2.1.2). These experiments 
suggest that bile acids increase translocation of both 4 and 20 kDa 
FITC dextran, which may contribute to the pathogenesis of gut barrier 
dysfunction in high-fat feeding. LPS has a lipid A component bound to 
a core sugar and a polysaccharide repeat. The molecular size of LPS 
varies tremendously, but for example the lipid A component of LPS 
from E. Coli is 1.80 kDa in size (Que et al., 2000), or  2.01  kDa when 
containing the core sugar (PubChem database). An average LPS 
molecule has a molecular size of approximately 4.29 kDa (PubChem 
database), which implies that it corresponds well to the size of FITC 
dextrans, and that more than 50% of its molecular mass is comprised 
of polysaccharide. The polysaccharide component, called O antigen, 
determines the serotype of the LPS molecule, as well as its 
hydrophobicity. The longer the O antigen, the more hydrophilic the LPS 
molecule is. Since the average LPS molecule contains more than 50% 
hydrophlilic polysaccharide, the hydrophilic FITC-dextrans used in 
these studies, 4 and 20 kDa, could be expected to somewhat represent 
the translocation of LPS. 
The Ussing chamber method allows measurement of permeability from 
selected tissue segments, whereas the in vivo gavage of FITC dextran 
does not distinguish between segments. Serum samples for the in vivo
method used in this study were taken 4 h after gavage, because at this 
time point FITC-dextran is visible by eye in the colon. Although it was 
suspected on these grounds that the in vivo method may measure 
permeability from also the large intestine, there is no evidence to 
confirm this assumption. The in vivo method may also  be  affected  by  
gastrointestinal transit time, whereas the Ussing chamber method 
holds no such bias. 
It should be stressed, however, that the Ussing chamber method 
cannot fully represent a physiological environment. Although care has 
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been taken to set pH, temperature and ion concentrations in the 
Ringer solution, the tissue segment is no longer connected to blood 
circulation. Despite carbogen gas flow in the chamber system, the 
tissue segment is inevitably ischemic to some degree. Moreover, tissue 
handling causes damage in cut areas. Given these circumstances, 
tissue segments cannot be held in the Ussing chamber for more than a 
few hours, depending on incubation conditions.
Although a diet high in fat elevates serum levels of LPS (Cani et al.,
2007a, 2007b, 2008; de La Serre et al., 2010; Everard et al., 2012; Kim 
et al., 2012; Laugerette et al., 2012; Serino et al.,  2012),  it  has  been 
questioned whether this indicates increased intestinal permeability, 
because high serum LPS levels may also result from decreased 
clearance or high prevalence of LPS-containing gut bacteria in the 
lumen (Teixeira et al., 2012a). Instead of measuring serum LPS levels, 
the  potential  of  LBP  as  a  marker  of  intestinal  permeability  was  
addressed  in  this  study.  LBP  was  measured  in  Study  II  from  serum  
and as liver expression. Although LBP is a marker mostly produced by 
the liver in response to LPS, these two parameters were surprisingly 
not correlated: although serum LBP level was increased in genetic 
obesity, liver LPB expression was unchanged. Previous studies have 
shown a relationship between serum LBP and obesity or fat mass (Sun 
et al., 2010, Moreno-Navarrete et al., 2011). Adipose tissue expression 
of LBP correlates with adipocyte size (Dr. Robert Caesar, personal 
communication), which suggests that LBP may also be excreted from 
adipose tissue. These reports indicate that serum LBP does not 
necessarily reflect serum LPS levels in obesity. 
6.1.2 Mouse models 
Obesity 
The C57Bl/6J mouse strain is a well-established healthy control that 
is often used as the basis for genetic modification (Rivera and 
Tessarollo, 2008). In this study, the C57Bl/6J mouse strain was used 
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for two obesity-models: the diet-induced obesity model and the 
commercially available genetically obese ob/ob model, which is bred 
into a C57Bl/6J background. There is a substantial difference in the 
mechanism of becoming obese between these two animal models. 
Whereas the diet-induced obese mice become obese on an energy-
dense high-fat diet, the ob/ob mouse is leptin-deficient and 
characterized by hyperphagia (Carroll et al., 2004), and thus becomes 
obese eating regular chow. The diet-induced obese mouse model better 
describes human obesity when compared to genetically obese models 
with single mutations. However, in the diet-induced obese model it 
cannot be verified whether any noted physiological changes are caused 
by dietary fat or obesity, i.e. expanding adipose tissue and alterations 
in its hormonal function. The genetically obese ob/ob model was used 
in this study to see whether obesity without dietary fat causes the 
modifications that are seen on a high-fat diet. 
In the ob/ob mouse model, it should be noted that effects of obesity 
and leptin deficiency cannot be entirely distinguished from each other. 
Not much is known of how leptin affects gut barrier function, but leptin 
pre-treatment is known to protect from intestinal ischemia-
reperfusion-induced mucosal damage in the rat (Sukhotnik et al., 
2007). It could then be speculated that leptin is protective to the 
epithelium, and leptin deficiency would predispose to barrier 
dysfunction. However, since permeability was not increased in ob/ob in 
the present study, leptin deficiency seems not to have affected the 
data.
Experimental colitis 
Study IV aimed to investigate whether dietary fat quantity or quality 
affects susceptibility to experimental colitis by a mechanism related to 
bile acid hydrophobicity. Colitis was induced by dextran sodium 
sulphate (DSS) in drinking water. The DSS-induced colitis model is 
commonly  used  as  a  model  of  inflammatory  bowel  disease,  to  study  
disease pathogenesis and therapeutic options (for review, Perše and 
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Cerar, 2012). The pathogenesis of DSS colitis is based on DSS-induced 
disruption of colonic epithelial cells and their tight-junctions, which 
enables translocation of luminal antigens (Perše and Cerar, 2012). A 
similar pathogenesis is proposed for human inflammatory bowel 
disease (see 2.1.6). In DSS mice, a loss of tight-junction proteins is 
observed after only one day of treatment, accompanied by an increased 
expression of inflammatory cytokines (Perše and Cerar, 2012). Later 
on, increased apoptosis and decreased proliferation aggravate barrier 
dysfunction. The DSS colitis model has been validated for its use in 
studies on IBD (Melgar et al., 2008). The severity of DSS colitis is 
regulated by the duration of DSS administration, and the 
concentration of  the drinking solution (Perše and Cerar,  2012).  In the 
present study, the 5% DSS solution caused severe inflammation, and 
in  some  mice  premature  death,  in  only  two  days  of  administration,  
although this dose has been used successfully in studies using the 
same method or in a pilot study performed for the present study (Liu et 
al., 2009; unpublished data). This may be due to differences in diet 
compositions, since in earlier studies mice were fed standard chow, 
which usually contains approximately 15% fiber, whereas the diets 
used in the present study contained only 6.5% fiber. Insoluble dietary 
fiber has been suggested to protect from the development of DSS colitis 
(Nagy-Szakal et al., 2013). 
6.1.3 Experimental diets 
This thesis included two dietary intervention trials in mice (Studies I 
and IV). These trials utilized commercially available open source diets. 
In Study I, a high-fat diet containing 60 E% fat (mostly lard) was used 
for the diet-induced obesity model. The alternative diet containing 45 
E%  fat  was  not  chosen,  because  it  was  unknown  at  the  time  of  
designing the study whether dietary fat has an effect at all. Thus the 
more extreme diet was chosen for the experiments. The diet used in the 
present study was much less extreme, however, than the previously 
used high-fat carbohydrate-free diets that are used to initiate diabetes 
(Cani et al., 2007a, 2007b, 2008; Serino et al., 2012). In Study IV, the 
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60  E% fat  diet  was  problematic,  since  lard  had to  be  included  in  the  
fish oil diet to be able to form a pelleted diet. For future studies on the 
quality  of  dietary  fat  in  inducing  barrier  dysfunction  it  could  be  
beneficial to use a 45 E% fat diet. This improves the pelletability of 
diets containing oils. 
Fish oil is generally perceived as anti-inflammatory, and because the 
present results are against this asssumption, they are easily critisized. 
However, a Cochrane systematic review and meta-analysis of nine 
studies on IBD concluded that there is insufficient data to recommend 
the use of fish oil to maintain remission in IBD (Turner et al. 2011). 
The high concentration of fish oil in the diet of Study IV may have 
increased intestinal bleeding in the fish oil group, because fish oil 
reduces platelet aggregation (for review, see Vanschoonbeek et al. 
2003). The aforementioned review claimed, however, that fish oil does 
not increase bruising or bleeding time in humans. With the present 
evidence it cannot be excluded that the anticoagulation tendency 
brought on by fish oil may have caused bias in data on DSS severity. 
The 10 E% fat control diet for Studies I and IV was paired to the high-
fat diet in all but fat and carbohydrate content. Instead of excess fat as 
lard, the control diet contained sucrose. It can be debated whether this 
is metabolically the best control in permeability research. Sucrose 
contains 50% fructose, which is suspected to increase translocation of 
endotoxins (Bergheim et al., 2008). At present, a low-sucrose diet 
paired for the high-fat diet used here is also available. From the view-
point of obesity research, however, the control diet used here could be 
more ideal in ad libitum studies than those with lower sucrose 
contents, because a diet high in sucrose forms a very hard pellet. As 
reported, diet texture is essential in weight development 
(Desmarchelier et al., 2013) - only pelleted diets resulted in a difference 
in weight gain, whereas with soft diets all mice developed obesity. As a 
compromise for permeability studies in obesity models, it could be 
advisable to use a low-sucrose control diet and slightly restrict food 
intake if a large weight-difference is desired.
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6.2 Effects of dietary fat and obesity on intestinal 
permeability
These  data  show  that  a  diet  high  in  saturated  fat  increases  the  
permeability of jejunum and colon to a fluorescent probe (Study I). It 
cannot be concluded with the present sample sizes, however, whether 
permeability of duodenum or ileum was increased or not. Previously, 
only four studies have shown with direct markers of permeability that 
high-fat feeding increases intestinal permeability in animals. Cani et al.
(2008) showed that a carbohydrate-free (i.e. high-fat) diet increases 
permeability, when measured with in vivo gavage of FITC dextran. Both 
Suzuki and Hara (2010) and De La Serre (2010) have shown with direct 
probes in vivo that dietary fat increases gut permeability in rats, 
although the later only saw a difference in obesity-prone, but not 
obesity-resistant rats. Only Serino et al. (2012) have measured 
permeability from different segments of the distal gut after feeding with 
a high-fat, carbohydrate-free diet. They reported a 1.5-2-fold 
permeability of colon in high-fat-fed mice compared to control, 
although the difference was non-significant. The present study is the 
first to measure permeability in four locations along the gut in mice on 
a high-fat diet. 
These data show that obesity without dietary fat does not affect 
intestinal permeability (Study II). This is supported by a finding in 
genetically obese rats (Suzuki and Hara, 2010). Cani et al. (2008, 2009) 
have studied ob/ob mice and report decreased tight-junction protein 
levels in obese mice compared to wild-type, but do not give gut 
permeability data for wild-type mice to be compared with the obese 
mice. Another report from Brun et al. (2008) shows increased intestinal 
permeability in ob/ob mice. All mice were fed regular chow, and there 
are no major differences in the method of measuring permeability, but 
the mice used in that study were three weeks younger and obtained 
from a different supplier than in the present study. This raises the 
question of whether impaired barrier function is a feature specific to 
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some distinct strain of ob/ob mice, but would not be related to obesity 
itself. Several studies report elevated blood endotoxins in genetically 
obese mice (Brun et al., 2007; Cani et al., 2008, 2009; Haub et al., 
2011).  It  cannot  be  concluded,  however,  whether  this  is  due  to  
increased permeability, impaired hepatic or intestinal clearance, or 
increased luminal production of LPS. 
Although several studies report that obese animals on a high-fat diet 
demonstrate increased permeability, the present results suggest that 
this is due to dietary fat, not obesity itself. 
6.3 Bile acids as a possible mechanism 
These data suggest that alterations in luminal bile acid profile have a 
role  in  the  pathogenesis  of  barrier  dysfunction  by  dietary  fat.  Study  I  
shows that fecal bile acid hydrophobicity and intestinal permeability 
are associated and are both increased by a high-fat diet. Although 
Suzuki and Hara proposed a role for bile acids in fat-induced barrier 
dysfunction (2010), the present study is the first one to show a 
correlation of bile acid profile alterations to gut permeability. Data from 
Study IV suggest that dietary fish oil may increase fecal bile acid 
hydrophobicity even further than dietary lard. The concentration of 
DCA was higher in feces of fish oil -fed mice compared to lard-fed mice. 
Although fecal bile acid hydrophobicity correlated with disease 
symptom severity, the impact of dietary fat quality on intestinal barrier 
function is yet to be determined.
Study III compared the luminal DCA concentrations of control mice to 
those of diet-induced obese mice in inducing barrier dysfunction. It is 
well known that DCA increases intestinal permeability (Chadwick et al., 
1979; Goerg et al., 1980; Argenzio and Whipp, 1983; Goerg et al., 
1983; Gyory and Chang, 1983; Henrikson et al., 1989; Fasano et al., 
1990; Fihn et al., 2003; Sun et al., 2004a, 2004b), as also shown both 
in vivo and ex vivo in Study III. However, this study is novel in finding 
that intestinal permeability was increased by DCA concentrations that 
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are found in the feces of diet-induced obese mice, but not by those 
found in the feces of control mice. 
The present data suggest that the mechanism by which DCA increases 
intestinal permeability is rather related to disruption of tissue 
structure than inflammation, since tissue COX-2 content was 
unchanged, although histological staining showed clear disruption of 
the epithelium. Moreover, suggestive data show that treatment with the 
anti-inflammatory dexamethasone did not reduce epithelial disruption, 
nor was tissue occludin content affected. Henrikson et al. (1989) have 
shown that DCA reversibly alters porcine colonic morphology at 3-15 
mM concentrations, with an irreversible disruption of the basal lamina 
at 21 mM. An earlier study suggested, however, that 2-8 mM DCA does 
not  disrupt  the  integrity  of  rat  colon,  when  imaged  with  electron  
microscopy (Goerg et al., 1982). Instead, it was proposed that shedding 
of colonic cells is an artefact caused by the loosening of tight-junctions, 
and that changes in permeability are caused by tight-junction 
modifications, not by disruption of cell membranes. In the present 
study, the possibility for such an artefact cannot be ruled out. Tissue 
occludin levels were not changed by DCA incubation (Study III), which 
does not support the suggestion by Goerg et al. (1982), although 
sample-size was small and other tight-junctions or their localization 
were  not  analyzed.  These  data  also  do  not  support  an  inflammatory  
mechanism, since tissue COX-2 content was unchanged. The co-
incubation of DCA with dexamethasone suggests that anti-
inflammatory treatment does not inhibit barrier dysfunction, although 
it  is  possible  that  the  incubation  time  was  too  short  for  this  drug  to  
have an effect. Thus, this study does not prove a mechanism of action 
for barrier-disruption by DCA. The present results tentatively suggest, 
however, that the induction of barrier leakage is not inflammation-
dependent.
To compare the effects of DCA to a more hydrophilic bile acid, 
experiments were conducted with UDCA. This bile acid had no effect on 
permeability itself, but prevented DCA-induced barrier dysfunction at a 
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0.6 mM concentration. UDCA has shown other gut-protective effects in 
several previous studies: it has protected against chemically or 
pharmacologically induced colitis (Bernardes-Silva et al., 2004; 
Kullmann et al., 1997a, 1997b) and colitis-associated adenocarcinoma 
(Loddenkemper et al., 2006) in rodents. 
UDCA protects lipid membranes from disruption and perturbation by 
DCA in vitro (Heuman and Bajaj, 1994; Rodrigues et al., 1998). Possible 
mechanisms of action include UDCA replacing DCA in the cell 
membrane or UDCA binding to the cell membrane and inducing a 
repelling negative charge towards the negatively charged DCA. These 
hypotheses are inadequate, however, since in the lack of cholesterol 
UDCA is as cytotoxic as DCA (Zhou et al., 2009b). Zhou et al. (2009b) 
showed that UDCA protects cell membranes from DCA, but only in the 
presence of cholesterol. These results may partly explain the large 
variation in response to DCA-UDCA-mixtures in the present Ussing 
chamber studies. Since UDCA requires membrane cholesterol to be 
cytoprotective, any possible variation in epithelial cholesterol between 
individuals could have affected the results of the present study. 
Moreover, UDCA was only protective at 0.6 mM, with 1 mM having no 
effect. It could be hypothesized that with a high UDCA concentration a 
depletion of membrane cholesterol prevented any further 
cytoprotection, and additional UDCA was cytotoxic. This would lead to 
a cut-off concentration of 0.6 mM for the barrier-protective effect of 
UDCA in the present study design.
UDCA protected from DCA-induced barrier dysfunction in colonic, but 
not jejunal preparations. It is unknown whether this is only a matter of 
concentrations or incubation conditions. Before arriving to the ileum, 
where most bile acids are absorbed, the luminal concentration of bile 
acids in jejunum is 2-3-fold compared to that in colon (Hagio et al.,
2009). This difference may have an impact on physiological defense 
mechanisms such as mucus excretion. Moreover, there are substantial 
differences in the microbial concentration of jejunum and colon, which 
may affect the host’s response to external stimuli.
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It is probable that in the physiological conditions in the intestine there 
are various factors protecting the intestine from the cytotoxicity of bile 
acids. Besides gut mucus and other factors that are lost in the ex vivo
setting of the Ussing chamber, there may be other bile acids capable of 
cytoprotection. -muricholic acid is another hydrophilic bile acid, 
which is primarily produced in the rodent liver (Lefebvre et al., 2009). 
Although it has not been tested in intestinal permeability, it has a 
similar beneficial effect against cholesterol gallstones, as that of UDCA 
(Wang and Tazuma, 2002). As a very hydrophilic bile acid, the efficacy 
of -muricholic in protecting from DCA cytotoxicity should be 
examined in further studies.
Besides UDCA, there may be many other luminal factors participating 
in  the  pathogenesis  of  barrier  dysfunction  by  DCA.  Due  to  the  gut  
microbiota, the gut lumen contains LPS, which constantly translocates 
to the submucosa at a low rate (for review, see Kelly et al., 2012). To 
the human immune system, LPS is highly inflammatory. DCA has been 
shown to provoke mucosal sensitivity to -lactoglobulin, perhaps by 
increasing translocation to the lamina propria (Baird and Cuthbert, 
1985). Analogically, it was hypothesized in this study that cytotoxic bile 
acids sensitize the gut to LPS-induced inflammation by promoting the 
translocation  of  LPS  to  the  lamina  propria.  The  results  show  a  
tendency for LPS to exacerbate DCA-induced barrier dysfunction. LPS 
alone, on the contrary, had no effect on intestinal permeability. 
Previous reports have also shown apically administered LPS not to 
increase permeability in colon (Emmanuel et al., 2007) or intestinal 
Caco-2 cells (Hanson et al., 2011) even at concentrations 100-fold 
compared to the ones used in the present study. However, bile acids 
have been reported to facilitate the translocation of LPS into human 
gut mucosa, as examined with confocal microscopy (Münch et al., 
2007). The present data suggest that once in the submucosa, LPS may 
increase gut permeability. This is supported by a previous study 
showing that basolateral administration of LPS to Caco-2 cells 
increases permeability (Hanson et al., 2011). 
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Together the findings of  this study imply that bile  acids may have an 
initiating role in the pathogenesis of gut barrier dysfunction, where LPS 
or other luminal antigens possibly play a secondary role. As illustrated 
in Figure 15, the novel hypothesis of the pathogenesis of gut barrier 
dysfunction, derived from the results of this study, suggests that 
dietary modifications in the fecal bile acid profile result in increased 
gut permeability and permit increased translocation of LPS. This LPS, 
in turn, causes submucosal inflammation and initiates a vicious cycle, 
which leads to metabolic endotoxemia. 
6.4 Clinical relevance 
Intestinal  barrier  dysfunction  is  related  to  an  increasing  array  of  
diseases common in the Western countries: inflammatory bowel 
diseases (IBD) (for review, see Goyette et al., 2007), irritable bowel 
syndrome (IBS) (for review, see Camilleri et al., 2012), type 1 diabetes 
(for review, see Vaarala, 2008), non-alcoholic fatty liver disease (for 
review, see Valenti et al., 2009) and allergy (for review, see Perrier and 
Corthésy, 2011). This thesis investigated the role of dietary fat, obesity 
and bile acids as causes for intestinal barrier dysfunction. The present 
results suggest that increased bile acid hydrophobicity in the large 
intestine impairs mucosal barrier function. Ursodeoxycholic acid 
appeared to be a potential therapeutic agent for the prevention or 
treatment of these pathophysiological events in mice. Options for other 
membrane-strengthening agents should be investigated, and their 
efficacy should be tested in humans.
The results of these animal and in vitro studies cannot be directly 
extrapolated into humans. There are differences in for example the bile 
acid metabolism, microbiota and gut mucosal immunology of mice and 
humans, which demonstrate a clear need for similar experiments in 
humans. One of the largest differences in murine and human bile acid 
metabolism is in the murine ability to metabolize DCA back into its 
primary bile acid. Surprisingly, this does not pose such a large 
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difference in their small intestinal DCA concentration, because of 
coprophagia in mice (Groen et al., 2006).
6.5 Future directions 
Although the present series of studies suggests that a diet high in fat 
modifies luminal bile acid profile, it is still unknown how dietary fat 
elicits these changes. Because luminal hydrophobicity was increased 
mostly  due  to  changes  in  secondary  or  tertiary  bile  acids,  it  could  be  
hypothesized, that these changes are caused by alterations in gut 
microbiota. Although preliminary evidence shows that a high-fat diet 
increases fecal 7-hydroxylase activity (Reddy et al., 1996), suggesting 
a difference in microbial metabolism, this assumption should be fully 
investigated in future research. It is also imperative to know how 
different dietary fats affect the bile acid pool, and how these changes 
alter gut epithelial function. In the present study, mice eating fish oil 
were more susceptible to death of DSS colitis than those eating lard. 
This interesting finding should be further investigated to see if the 
effect can be replicated on lower doses of fish oil and DSS. 
Another recently published paper proposed that increased biliary 
excretion of taurocholic acid in mice favors the growth of Bilophila 
wadsworthia, which is suspected to be a colitis-predisposing gut 
microbe (Devkota et al., 2012). The authors did not discuss the fact 
that  taurocholic  acid  is  mostly  unconjugated  in  colon.  It  is  thus  
unknown whether the effect was attributable to taurocholic acid itself 
or its metabolites. Nevertheless, it is important to know how bile acids 
affect  metabolism  and  gut  mucosal  function  in  all  its  forms  –  from  
biliary bile salts to serum and fecal bile acids. Peter J. Turnbaugh, a 
pioneer in research on obesity and gut microbiota, also emphasizes the 
need to continue research on the effects of diet on gut microbiota and 
bile acids (Turnbaugh, 2012). Bile acids have indeed raised interest in 
gut microbiota research and it is time to combine these two areas of 
obesity research. 
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7 CONCLUSIONS 
The present series of studies investigated the role of dietary fat, obesity 
and bile acids in the pathogenesis of gut barrier dysfunction using 
mice on a high-fat diet, genetically obese mice and tissue preparations 
in vitro. The main findings are as follows:
i. Intestinal permeability is increased, especially in jejunum and 
colon, by dietary fat, but not by obesity itself. 
ii. Dietary fat alters not just fecal bile acid concentration, but also 
fecal bile acid profile. Lard and fish oil severely increase fecal 
bile  acid  hydrophobicity  compared  to  control.  Dietary  fish  oil  
seems to induce a more hydrophobic bile acid profile than 
dietary lard. Obesity has no effect on bile acid hydrophobicity. 
iii. Fecal bile acid hydrophobicity is positively correlated with 
intestinal permeability. A very hydrophobic bile acid, deoxycholic 
acid, impairs barrier function, whereas the more hydrophilic 
ursodeoxycholic acid may even protect gut epithelium from bile 
acid cytotoxicity. The mechanism of bile acid -induced 
disruption of the epithelium seems inflammation-independent. 
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